

CITATION REPORT

List of articles citing

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

DOI: 10.1056/nejm199803263381301

New England Journal of Medicine, 1998, 338, 853-60.

Source: <https://exaly.com/paper-pdf/29466995/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2208	VARICELLA ZOSTER AND OTHER VIRUS-RELATED CEREBRAL VASCULOPATHY. 17-26		
2207	[Clinical studies on the use of protease inhibitors in HIV infection. Answers and questions]. 1998 , 39, 927-34		
2206	Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. 1998 , 28, 4177-87		23
2205	Human immunodeficiency virus mutation and changes in CD4 T-cell levels during antiretroviral therapy. 1998 , 17, 301-3		2
2204	Decreasing cryptosporidiosis among HIV-infected persons in New York City, 1995-1997. 1998 , 75, 601-2		7
2203	Chemical protein synthesis. 1998 , 9, 412-26		88
2202	Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands. 1998 , 8, 3531-6		6
2201	HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. 1998 , 13, 586-93		90
2200	Highly active antiretroviral therapy. 1998 , 351, 1058-1059		9
2199	Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. 1998 , 352, 1725-30		1042
2198	Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. 1998 , 352, 185-90		134
2197	Antiretroviral treatment in 1998. 1998 , 352, 1919-22		75
2196	Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. 1998 , 1, 255-65		69
2195	New antiviral agents for dermatologic disease. 1998 , 17, 243-55		2
2194	Human immunodeficiency virus infection, Part II. 1998 , 44, 677-716		5
2193	Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. 1998 , 3, 39-47		9
2192	The compromised traveler. 1998 , 12, 369-412		46

2191	The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. <i>New England Journal of Medicine</i> , 1998 , 339, 1897-904	59.2	428
2190	General Solid-Phase Synthesis Approach To Prepare Mechanism-Based Aspartyl Protease Inhibitor Libraries. Identification of Potent Cathepsin D Inhibitors. 1998 , 120, 9735-9747		59
2189	Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. 1998 , 126, 817-22		127
2188	Nelfinavir. A review of its therapeutic efficacy in HIV infection. 1998 , 56, 147-67		69
2187	HIV treatment failure: testing for HIV resistance in clinical practice. 1998 , 280, 1871-3		166
2186	A national tissue bank to track HIV eradication and immune reconstruction. 1998 , 280, 1865-6		11
2185	Toward HIV eradication or remission: the tasks ahead. 1998 , 280, 1866-7		151
2184	Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. <i>New England Journal of Medicine</i> , 1998 , 339, 1261-8	59.2	256
2183	Highly active antiretroviral therapy (HAART) and prolonged survival of a patient with an HIV-related Burkitt lymphoma, despite an intracardiac relapse. 1998 , 9, 773-5		6
2182	HIV/AIDS in 1998--gaining the upper hand?. 1998 , 280, 87-8		14
2181	Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. 1998 , 280, 1497-503		528
2180	Inotropic therapy for heart failure. <i>New England Journal of Medicine</i> , 1998 , 339, 1848-50	59.2	86
2179	Influenza vaccination and the Guillain-Barré syndrome. <i>New England Journal of Medicine</i> , 1998 , 339, 1845-6	59.2	35
2178	Effects of pregnancy and delivery on disease activity in multiple sclerosis. <i>New England Journal of Medicine</i> , 1998 , 339, 339-40	59.2	27
2177	Transmission of multidrug-resistant human immunodeficiency virus--the wake-up call. <i>New England Journal of Medicine</i> , 1998 , 339, 341-3	59.2	49
2176	Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 1998 , 339, 405-6	59.2	99
2175	Therapeutic strategies for HIV infection--time to think hard. <i>New England Journal of Medicine</i> , 1998 , 339, 1319-21	59.2	22
2174	Potential for the transmission of HIV-1 despite highly active antiretroviral therapy. <i>New England Journal of Medicine</i> , 1998 , 339, 1846-8	59.2	14

2173	Risk adjustment or risk avoidance?. <i>New England Journal of Medicine</i> , 1998 , 339, 1925-6	59.2	14
2172	Caring for people with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 1998 , 339, 1926-8	59.2	11
2171	Progress and problems in the fight against AIDS. <i>New England Journal of Medicine</i> , 1998 , 338, 906-8	59.2	62
2170	Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. <i>New England Journal of Medicine</i> , 1998 , 339, 1803-9	59.2	387
2169	Paying more fairly for Medicare capitated care. <i>New England Journal of Medicine</i> , 1998 , 339, 1933-8	59.2	64
2168	The chest-pain unit--ready for prime time?. <i>New England Journal of Medicine</i> , 1998 , 339, 1930-2	59.2	20
2167	Antiretroviral therapy; where are we going?. 1998 , 12, 515-8		
2166	Acyclovir for recurrent herpes simplex virus ocular disease. <i>New England Journal of Medicine</i> , 1998 , 339, 340-1	59.2	24
2165	Failure of prophylaxis against PCP in patients with HIV infection. 1998 , 12, 843-8		3
2164	Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure. 1998 , 280, 28		55
2163	Adherence to Antiretroviral Therapy in Correctional Settings. 1998 , 5, 179-200		1
2162	Making medicines safer--the need for an independent drug safety board. <i>New England Journal of Medicine</i> , 1998 , 339, 1851-4	59.2	107
2161	Helicobacter pylori and nonulcer dyspepsia. <i>New England Journal of Medicine</i> , 1998 , 339, 1928-30	59.2	37
2160	Barriers to use of free antiretroviral therapy in injection drug users. 1998 , 280, 547-9		426
2159	Trends in health care R&D and technology innovation. 1998 , 17, 111-9		35
2158	Strategies for Antiviral Drug Discovery. 1998 , 9, 1-20		30
2157	HIV in Scotland--the challenge ahead. 1998 , 43, 168-72		2
2156	Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. 1998 , 19, 182-8		22

2155	Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. 1998 , 12, F217-23	134
2154	Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 , 12, 1309-15	8
2153	Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected individuals. 1998 , 12, 2417-23	6
2152	The era of adherence to HIV therapy. 1998 , 129, 503-5	133
2151	HIV disease progression in Australia in the time of combination antiretroviral therapies. 1998 , 169, 469-472	46
2150	Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. 1998 , 129, 779-86	29
2149	You've gotta have HAART. 1998 , 169, 456-457	5
2148	Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. 1999 , 159, 1771-6	70
2147	Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. 1999 , 70, 867-73	44
2146	Gaining ground in progressive multifocal leukoencephalopathy. 1999 , 52, 440-1	1
2145	Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. 1999 , 43, 2607-11	89
2144	A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. 1999 , 43, 1961-7	162
2143	New insights into human cryptosporidiosis. 1999 , 12, 554-63	125
2142	[Antibiotics, new pathogens, new drug resistance]. 1999 , 56, 691-7	
2141	Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. 1999 , 43, 2869-72	25
2140	Gastrointestinal manifestations of HIV infection. 1999 , 60, 24-8	3
2139	Role of endoscopy in the investigation of upper gastrointestinal symptoms in HIV-infected patients. 1999 , 13, 305-10	5
2138	Morbidity and mortality related to human immunodeficiency virus in Canadian men and women, 1987-94. 1999 , 90, 127-32	4

2137	Impact of Protease Inhibitors on Drug Use and Cost for Hospital Patients with HIV. 1999 , 15, 212-218	1
2136	Antiretroviral Medication Administration and HIV-Positive Patients: A Practical Approach. 1999 , 34, 1186-1195	
2135	Long-term remission for disseminated Mycobacterium avium-intracellulare complex associated with antibody deficiency. 1999 , 103, E13	
2134	HIV treatment: where are we now?. 1999 , 10, 21-25	
2133	Costs of HIV medical care in the era of highly active antiretroviral therapy. 1999 , 13, 963-9	104
2132	HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. 1999 , 13, F35-43	313
2131	Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. 1999 , 13, 1115-22	68
2130	Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. 1999 , 13, 1889-97	135
2129	Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. 1999 , 13, 779-89	63
2128	Recent dramatic decrease in AIDS cases and HIV-related deaths contrasts with stable rate of new HIV-positive patients detected in Lyon, France, from 1988 to 1997. 1999 , 20, 316-7	3
2127	Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. 1999 , 20, 28-33	49
2126	Dehydroepiandrosterone Sulfate (DHEAS) and Testosterone: Relation to HIV Illness Stage and Progression Over One Year. 1999 , 22, 146	11
2125	Has the spectrum of AIDS-defining illnesses been changing since the introduction of new treatments and combination of treatments?. 1999 , 20, 515-6	11
2124	Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. 1999 , 21, 20-5	110
2123	Insulin resistance in HIV protease inhibitor-associated diabetes. 1999 , 21, 209-16	112
2122	HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. 1999 , 22, 407-8	8
2121	Assessing the impact of highly active antiretroviral therapy on AIDS and death. 1999 , 13, 2165-6	5
2120	Cerebrospinal fluid and plasma HIV-1 RNA stability at 4 degrees C. 1999 , 13, 1281-2	3

2119	High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. 1999 , 22, 132-8	12
2118	Immune activation and plasma viral load in HIV-infected African individuals. 1999 , 13, 1283-5	2
2117	Reply. 1999 , 13, 1285	
2116	Predictors of optimal virological response to potent antiretroviral therapy. 1999 , 13, 1873-80	141
2115	Natural history of HIV infection in the era of combination antiretroviral therapy. 1999 , 13, 1933-42	316
2114	Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine. 1999 , 22, 101-3	9
2113	Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. 1999 , 13, 1249-53	298
2112	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. 1999 , 21, 401	15
2111	Poor penetration of the male genital tract by HIV-1 protease inhibitors. 1999 , 13, 859-60	42
2110	HIV-associated non-mycobacterial sepsis-bacteraemia, before and during the highly active antiretroviral therapy era. 1999 , 13, 1274-6	13
2109	Highly active antiretroviral therapy among drug users in Amsterdam: self-perceived reasons for not receiving therapy. 1999 , 13, 1280-1	5
2108	Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. 1999 , 13, 1549-56	47
2107	HIV and combination therapy: meeting the challenge of a new era. 1999 , 8, 39-43	3
2106	Assessments of the coverage of HIV-related care by public programs: a survey of AIDS service organizations. 1999 , 29, 19-42	2
2105	Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. 1999 , 159, 2009-13	90
2104	Opportunistic viral infections in the setting of human immunodeficiency virus. 1999 , 19, 185-92	20
2103	Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. 1999 , 282, 1627-32	340
2102	Changing trends in cytomegalovirus retinitis with highly active anti-retroviral therapy (HAART). 1999 , 13 (Pt 3a), 275-6	1

2101	Interventricular septal abscess formation in an HIV-positive man. 1999 , 10, 749-50		1
2100	Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes. 1999 , 31, 37-42		6
2099	The lung in the immunocompromised patient. Infectious complications Part 1. 1999 , 66, 95-109		37
2098	Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. <i>New England Journal of Medicine</i> , 1999 , 340, 1063-70	59.2	410
2097	Discontinuation of primary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. <i>New England Journal of Medicine</i> , 1999 , 340, 1301-6	59.2	235
2096	Residual HIV-1 disease in the era of highly active antiretroviral therapy. <i>New England Journal of Medicine</i> , 1999 , 340, 1672-4	59.2	31
2095	Insomnia in prion diseases: sporadic and familial. <i>New England Journal of Medicine</i> , 1999 , 340, 1675-7	59.2	15
2094	The relation between volume and outcome in health care. <i>New England Journal of Medicine</i> , 1999 , 340, 1677-9	59.2	108
2093	The AIDS epidemic--considerations for the 21st century. <i>New England Journal of Medicine</i> , 1999 , 341, 1046-50	59.2	187
2092	Editorial independence. <i>New England Journal of Medicine</i> , 1999 , 340, 1671-2	59.2	17
2091	HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. 1999 , 52, 623-5		205
2090	Trends in infectious disease mortality in the United States during the 20th century. 1999 , 281, 61-6		450
2089	Editorial Response: What Is Antiretroviral Failure?. 1999 , 29, 82-84		3
2088	Editorial response: Prophylaxis for <i>Pneumocystis carinii</i> pneumonia--an evolving tale of two populations. 1999 , 29, 784-6		3
2087	Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. 1999 , 179, 697-700		179
2086	Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. 1999 , 179, 808-16		70
2085	Management of CMV disease in HIV infection. 1999 , 10, 211-6; quiz 216-9		3
2084	Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. 1999 , 179, 1254-8		171

2083	Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment. 1999 , 29, 35-43	19
2082	Cytomegalovirus retinitis in persons with AIDS--a shift in the treatment paradigm?. 1999 , 28, 534-6	3
2081	Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. 1999 , 29, 1423-30	70
2080	Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. 1999 , 179, 717-20	220
2079	Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. 1999 , 180, 847-9	66
2078	Doctor, You've Got E-mail. 1999 , 282, 729	6
2077	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. 1999 , 282, 2220-6	341
2076	Longer-term immunologic effects and side effects of successful antiretroviral therapy. 1999 , 29, 12-8	31
2075	HIV-1 drug resistance in newly infected individuals. 1999 , 282, 1135-41	353
2074	Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. 1999 , 180, 359-68	49
2073	Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. 1999 , 15, 1631-8	72
2072	Primary HIV-1 resistance: a new phase in the epidemic?. 1999 , 282, 1177-9	40
2071	Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. 1999 , 282, 2305-12	161
2070	Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy. 1999 , 180, 1057-63	40
2069	Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. 1999 , 53, 782-9	199
2068	Monitoring cytomegalovirus retinitis prevalence in an HIV-seropositive cohort: the assessment of improvements observed following the introduction of highly active antiretroviral triple therapy. 1999 , 10, 652-6	1
2067	Pharmacologic considerations for therapeutic success with antiretroviral agents. 1999 , 33, 989-95	38
2066	A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of <i>Pneumocystis carinii</i> pneumonia in human immunodeficiency virus-infected persons. Terry Beinr Community Programs for Clinical Research on AIDS (CPCRA). 1999 , 29, 775-83	68

2065	Changing patterns of HIV related ocular disease. 1999 , 75, 18-20	8
2064	Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. 1999 , 75, 218-24	24
2063	Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. 1999 , 179, 1375-81	146
2062	HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions. 1999 , 13, 153-63	38
2061	Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, zidovudine, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. 1999 , 15, 963-72	20
2060	Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. 1999 , 15, 1405-12	61
2059	Latent reservoirs of HIV: obstacles to the eradication of virus. 1999 , 96, 10958-61	292
2058	Improved prognosis in patients with acquired immunodeficiency syndrome-related lymphoma. 1999 , 14, 349-52	7
2057	Impact of protease inhibitors on the outcome of human immunodeficiency virus-infected patients with chronic diarrhea. 1999 , 94, 3553-9	30
2056	Perception of quality of life of persons with HIV/AIDS and maintenance of nutritional parameters while on protease inhibitors. 1999 , 13, 427-33	7
2055	Use of protease inhibitors among persons with AIDS in Los Angeles County. 1999 , 11, 147-55	24
2054	The rabbit study: zidovudine and zalcitabine in combination in zidovudine-experienced and previously untreated patients. 1999 , 15, 1181-9	5
2053	Immunologic and viral markers of HIV-1 disease progression: implications for dentistry. 1999 , 130, 1313-22	17
2052	Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels. 1999 , 15, 1249-54	17
2051	Expression of a novel Nef epitope on the surface of HIV type 1-infected cells. 1999 , 15, 1001-9	10
2050	Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study. 1999 , 180, 1784-9	49
2049	In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. 1999 , 17, 345-56	30
2048	Economic issues and antiretroviral therapy in developing countries. 1999 , 93, 1-3	10

2047	Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents. 1999 , 9, 3063-8	38
2046	Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. 1999 , 39, 193-7	6
2045	HIV and tuberculosis co-infection in an inner London hospital--a prospective anonymized seroprevalence study. 1999 , 38, 162-6	14
2044	Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. 1999 , 51, 223-30	29
2043	Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. 1999 , 29, 723-32	32
2042	HIV-Protease inhibitors reduce cell adherence of <i>Candida albicans</i> strains by inhibition of yeast secreted aspartic proteases. 1999 , 113, 747-51	86
2041	When should we delay highly active antiretroviral therapy?. 1999 , 14, 446-8	40
2040	Delays in protease inhibitor use in clinical practice. 1999 , 14, 395-401	93
2039	Gastrointestinal and respiratory <i>Mycobacterium avium</i> colonization and development of disseminated infection in HIV-positive patients. 1999 , 5, 176-177	1
2038	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. 1999 , 5, 512-7	1681
2037	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. 1999 , 5, 651-5	365
2036	[Infectiology]. 1999 , 40, 369-80	1
2035	Cystoid macular edema in a patient with acquired immunodeficiency syndrome and past ocular history of cytomegalovirus retinitis after initiation of protease inhibitors. 1999 , 97, 311-5	2
2034	Mother Knows Best? Mother and Child Report of Behavioral Difficulties of Children of HIV-Infected Mothers. 1999 , 21, 191-206	16
2033	The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review. 1999 , 148, 73-8	39
2032	Prospective study of healing time after hemorrhoidectomy: influence of HIV infection, acquired immunodeficiency syndrome, and anal wound infection. 1999 , 42, 1140-4	66
2031	Pharmacological issues relating to viral resistance. 1999 , 27 Suppl 2, S42-4	9
2030	Association between submaximal suppression of HIV replication and use of drug combinations without protease inhibitors. 1999 , 18, 604-5	

2029	Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis. 1999 , 1, 80-88	13
2028	Immune Reconstitution and the Consequences for Opportunistic Infection Treatment and Prevention. 1999 , 1, 99-104	4
2027	Reservoirs for HIV-1. 1999 , 1, 298-304	6
2026	HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. 1999 , 19, 281-98	45
2025	Preface. 1999 , 39, 1-3	
2024	AIDS-associated malignancies: research perspectives. 1999 , 1423, C1-9	9
2023	Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. 1999 , 15, 453-7	19
2022	Regulatory functions of Cdk9 and of cyclin T1 in HIV Tat transactivation pathway gene expression. 1999 , 75, 357-368	23
2021	Why is the efficacy of HAART so durable?. 1999 , 9, 1-2	3
2020	Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naive T cells following triple-drug therapy for HIV type 1 infection. 1999 , 15, 435-43	26
2019	Pathogenesis of HIV infection and implications for clinical practice. 1999 , 19, 121-131	
2018	Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains. 1999 , 42, 4054-61	51
2017	Vaccines. 1999 ,	
2016	In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. 1999 , 180, 448-53	179
2015	Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. 1999 , 16, 307-15	26
2014	Fomivirsen: monthly local injections now an option for treating CMV retinitis. 1999 , 14, 1-4	1
2013	Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study. 1999 , 31, 489-93	9
2012	Epidemiological considerations about retinal opportunistic infections in HIV-infected patients in France. 1999 , 7, 167-71	5

2011	Salvage treatment against human immunodeficiency virus. 1999 , 31, 253-60	9
2010	Rifabutin prophylaxis against Mycobacterium avium complex infections in HIV-infected patients: impact on the incidence of campylobacteriosis. 1999 , 13, 467-72	4
2009	Current and novel agents for the treatment of cytomegalovirus retinitis. 1999 , 2, 289-97	2
2008	Partner notification as a prevention strategy: a social system perspective. 1999 , 13, 327-34	1
2007	New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy. 1999 , 7, 179-88	10
2006	Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice. 1999 , 31, 495-9	13
2005	Resolution of recalcitrant hand warts in an HIV-infected patient treated with potent antiretroviral therapy. 1999 , 40, 818-21	14
2004	Proposed alternatives for the use of anti-HIV drugs: is it appropriate?. 1999 , 2, 71-72	
2003	Evaluation of adherence to a triple antiretroviral therapy in HIV-positive patients. 1999 , 10, 202-205	4
2002	Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). 1999 , 9, 349-57	68
2001	Lipid abnormalities associated with protease inhibitors. 1999 , 10, 22-30	13
2000	Intervention for hyperlipidemia associated with protease inhibitors. 1999 , 10, 55-69	17
1999	Immune reconstitution after combination antiretroviral therapy. 1999 , 19, 93-98	
1998	[Advances in the therapy of HIV infection and implications for clinical research]. 1999 , 20, 217-9	
1997	Home parenteral nutrition in adults: a European multicentre survey in 1997. 1999 , 18, 135-140	181
1996	Lipodystrophy in HIV-1-infected patients. 1999 , 354, 868	8
1995	Are European-specific guidelines needed for prevention of opportunistic infections in HIV-1?. 1999 , 354, 1305-6	2
1994	Are disability weights universal?. 1999 , 354, 1306	10

1993	Hypoglycaemia and driving. 1999 , 354, 1306	1
1992	Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. 1999 , 353, 1974	15
1991	Discontinuation of prophylaxis for <i>Pneumocystis carinii</i> pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. 1999 , 353, 201-3	167
1990	Prospects for hand transplantation. 1999 , 353, 1286-7	32
1989	Withdrawal of prophylaxis against <i>Pneumocystis carinii</i> pneumonia. 1999 , 353, 1287	3
1988	Relevance of AIDS treatment with two nucleoside analogues alone. 1999 , 353, 1989-90	3
1987	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. 1999 , 353, 863-8	812
1986	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. 1999 , 353, 1293-8	174
1985	Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. 1999 , 354, 697-8	13
1984	Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy. 1999 , 21, 1313-20	3
1983	Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. 1999 , 135, 675-82	29
1982	Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features. 1999 , 17, 445-71, vii	33
1981	Comparative tolerability of therapies for cytomegalovirus retinitis. 1999 , 21, 203-24	13
1980	Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. 1999 , 36, 289-304	227
1979	Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management. 1999 , 57, 735-41	10
1978	Indinavir: a review of its use in the management of HIV infection. 1999 , 58, 1165-203	65
1977	Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. 1999 , 17, 625-56	449
1976	Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. <i>New England Journal of Medicine</i> , 1999 , 340, 1614-22	59.2 527

1975	Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. 1999 , 42, 3203-9	147
1974	Risk factors for rebleeding and mortality from acute upper gastrointestinal hemorrhage in human immunodeficiency virus infection. 1999 , 94, 358-63	17
1973	Analogy of human immunodeficiency virus to hepatitis C virus: the human immunodeficiency model. 1999 , 107, 41S-44S	73
1972	Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. 1999 , 127, 329-39	64
1971	Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. 1999 , 128, 250-1	23
1970	1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Infectious Diseases Society of American. 1999 , 131, 873-908	13
1969	Antiretroviral Therapy in HIV-infected Pregnant Women. 1999 , 21, 351-361	
1968	A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. 1999 , 45, 48-55	15
1967	Cytomegalovirus Retinitis in Advanced HIV-Infected Patients Treated With Protease Inhibitors: Incidence and Outcome Over 2 Years. 1999 , 22, 228	4
1966	Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy (HAART). 1999 , 317, 318-335	11
1965	Lipodystrophy associated with nevirapine-containing antiretroviral therapies. 1999 , 13, 865-7	33
1964	Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. 1999 , 13, F59-62	176
1963	The quality of patient-doctor communication about end-of-life care: a study of patients with advanced AIDS and their primary care clinicians. 1999 , 13, 1123-31	96
1962	Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. 1999 , 13, F71-7	79
1961	Improved therapies for HIV infection and AIDS--implications for primary care. 1999 , 12, 97-9	2
1960	Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. 1999 , 13, 669-76	90
1959	The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. 1999 , 13, 1255-61	41
1958	Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. 1999 , 13, 1687-95	102

1957	Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group. 1999 , 13, 249-55	77
1956	The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. 1999 , 13, 415-8	81
1955	Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children. 1999 , 13, 863-4	30
1954	Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine. 1999 , 13, 864-5	4
1953	The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. 1999 , 13, 1099-107	399
1952	Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. 1999 , 13, 1273-4	32
1951	Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naïve patients. 1999 , 13, 1276-8	6
1950	Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. 1999 , 13, 2547-54	58
1949	A prospective study of HIV disease progression in female and male drug users. 1999 , 13, 257-62	93
1948	Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. 1999 , 13, 359-65	38
1947	Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV drugs. 1999 , 13, 869	5
1946	Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidémiologie Clinique de Sida en Aquitaine (GECSA). 1999 , 13, F115-21	94
1945	Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy. 1999 , 13, 867	5
1944	The interaction of opportunistic infections and HIV replication. 1999 , 13, 1603-6	9
1943	Adherence communication: a qualitative analysis of physician-patient dialogue. 1999 , 13, 1771-8	46
1942	Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. 1999 , 13, 2157-64	34
1941	CD4 cell counts at the third month of HAART may predict clinical failure. 1999 , 13, 1669-76	43
1940	Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. 1999 , 13, 177-84	109

1939	Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. 1999 , 13, 957-62	110
1938	Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. 1999 , 13, 1207-12	36
1937	A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey. 1999 , 13, 1727-35	54
1936	Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. 1999 , 20, 122-8	62
1935	High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. 1999 , 13, 870-1	20
1934	Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group. 1999 , 13, 1497-502	36
1933	Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. 1999 , 13, 2281-8	19
1932	Management of chronic hepatitis C in HIV-infected patients. 1999 , 13, 539-46	69
1931	Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. 1999 , 13, F23-8	108
1930	Antiphospholipid antibodies are an epiphenomenon in HIV-infected patients. 1999 , 13, 1282-3	14
1929	Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. Lazio AIDS Surveillance Collaborative Group. 1999 , 13, 2125-31	20
1928	Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling. 1999 , 13, 1569-76	21
1927	Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. 1999 , 13, 1763-9	448
1926	A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. 1999 , 13, 2411-20	25
1925	Ocular manifestations of HIV infection. 1999 , 10, 431-7	19
1924	Cytotoxic T lymphocyte recognition of HLA-B*5101-restricted HIV-1 Rev epitope which is naturally processed in HIV-1-infected cells. 1999 , 13, 861-3	3
1923	Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. 1999 , 13, 868-9	36
1922	Analysis of the CC chemokine receptor 5 m303 mutation in infants born to HIV-1-seropositive mothers. 1999 , 13, 871-2	8

1921	Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. 1999 , 13, F63-70	362
1920	Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?. 1999 , 13, 1278-9	3
1919	Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. 1999 , 13, 1351-7	83
1918	Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?. 1999 , 13, 1647-51	77
1917	Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. 1999 , 22, 430-6	10
1916	Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. 1999 , 22, 461-6	20
1915	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. 1999 , 22, 430	9
1914	Intravenous Drug Use, Relationship With Providers, and Stage of HIV Disease Influence the Prescription Rates of Protease Inhibitors. 1999 , 22, 461	21
1913	Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. 1999 , 21, 228-35	32
1912	Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV illness stage and progression over one year. 1999 , 22, 146-54	18
1911	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. 1999 , 22, 369	43
1910	Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. 1999 , 21, 401	36
1909	Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years. 1999 , 22, 228-34	13
1908	A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. 1999 , 22, 369-78	108
1907	Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS). 1999 , 22, 65-70	34
1906	High-Dose Saquinavir Plus Ritonavir: Long-Term Efficacy in HIV-Positive Protease Inhibitor-Experienced Patients and Predictors of Virologic Response. 1999 , 22, 132	12
1905	HAART Is Effective as Anti-Kaposi's Sarcoma Therapy Only After Remission Has Been Induced by Chemotherapy. 1999 , 22, 407	13
1904	Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. 1999 , 131, 81-7	624

1903	Behavioral Practices Regarding Combination Therapies for HIV/AIDS. 1999 , 24, 81-88	12
1902	A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. 1999 , 38, 302-3	20
1901	Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and Toxoplasma infection. 2000 , 39, 1111-4	16
1900	8-Difluoromethoxy-4-quinolone derivatives as anti-feline immunodeficiency virus (FIV) agents: important structural features for inhibitory activity of FIV replication. 2000 , 62, 499-504	1
1899	3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. 2000 , 133, 35-9	144
1898	Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. 2000 , 133, 21-30	2278
1897	Mortality among men using homeless shelters in Toronto, Ontario. 2000 , 283, 2152-7	259
1896	Clinical Spectrum, Morbidity, and Mortality of Acquired Immunodeficiency Syndrome in Taiwan: A 5-Year Prospective Study. 2000 , 24, 378-385	8
1895	Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. 2000 , 320, 117-23	29
1894	Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. 2000 , 160, 1123-32	181
1893	Cancer of the Anal Canal and HIV Infection: Toxicity and Results of Organ Preservation with Radiochemotherapy or Radiotherapy. 2000 , 23, 134-137	
1892	Clinical aspects of human cryptosporidiosis. 2000 , 6, 50-74	52
1891	Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men.. 2000 , 19, 134-145	190
1890	Antiretroviral therapy: time to think strategically. 2000 , 132, 320-2	6
1889	HIV: Past, present, and future. 2000 , 107, 109-113	
1888	Issues facing TB control (6). Tuberculosis control in sub-Saharan Africa in the face of HIV and AIDS. 2000 , 45, 47-50; discussion 51	3
1887	Effect of cryopreservation on measurement of cytomegalovirus-specific cellular immune responses in HIV-infected patients. 2000 , 25, 109-14	14
1886	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. 2000 , 14, 2635-42	63

1885	Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfecting patients. 2000 , 14, 2239-46	55
1884	Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. 2000 , 25, 312-21	107
1883	Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. 2000 , 23, 35-43	263
1882	HIV-infected parents and their children in the United States. 2000 , 90, 1074-81	93
1881	Relation of lean body mass to health-related quality of life in persons with HIV. 2000 , 24, 137-46	14
1880	Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?. 2000 , 24, 475-82	82
1879	Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. 2000 , 24, 227-31	22
1878	Erratum. 2000 , 8, 100-105	
1877	Trends in Prescriptions for Highly Active Antiretroviral Therapy in Four New York City HIV Clinics. 2000 , 23, 178-183	4
1876	Dissociation of Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy. 2000 , 23, 314-320	12
1875	Mortality for Liver Disease in Patients With HIV Infection: A Cohort Study. 2000 , 24, 211-217	82
1874	Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?. 2000 , 24, 475-482	80
1873	Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. 2000 , 25, 71-6	20
1872	Potential interventions for HIV/AIDS wasting: an overview. 2000 , 25 Suppl 1, S74-80	10
1871	Physician-patient communication in HIV disease: the importance of patient, physician, and visit characteristics. 2000 , 25, 417-25	27
1870	Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. 2000 , 25, 426-33	26
1869	Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection. 2000 , 23, 35-43	320
1868	Relation of Lean Body Mass to Health-Related Quality of Life in Persons With HIV. 2000 , 24, 137-146	33

1867	Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. 2000 , 23, 236-45	62
1866	Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. 2000 , 23, 302-13	7
1865	Mortality for liver disease in patients with HIV infection: a cohort study. 2000 , 24, 211-7	169
1864	Safety, Tolerability, and Antiretroviral Effects of Ritonavir-Nelfinavir Combination Therapy Administered for 48 Weeks. 2000 , 25, 322-328	9
1863	Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV-1 Infected Patients Receiving Antiretroviral Therapy. 2000 , 25, 426-433	35
1862	Differential Impact of Combined Antiretroviral Therapy on the Survival of Italian Patients With Specific AIDS-Defining Illnesses. 2000 , 25, 451-458	45
1861	Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. 2000 , 23, 178-83	16
1860	Physician-Patient Communication in HIV Disease: The Importance of Patient, Physician, and Visit Characteristics. 2000 , 25, 417-425	40
1859	Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. 2000 , 23, 314-20	19
1858	Survival in children with perinatal HIV infection and very low CD4 lymphocyte counts. 2000 , 25, 269-75	4
1857	Prevalence and Predictors of Highly Active Antiretroviral Therapy Use in Patients With HIV Infection in the United States. 2000 , 25, 115-123	142
1856	When can cytomegalovirus prophylaxis and maintenance therapy be stopped in HIV disease?. 2000 , 13, 637-641	8
1855	Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study. 2000 , 14, F103-10	35
1854	High prevalence of HIV infection among young men who have sex with men in New York City. 2000 , 14, 1793-800	80
1853	The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. 2000 , 14, 2129-36	33
1852	Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with 500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 2000 , 14, 23-9	29
1851	Effects of case management and new drugs on Medicaid AIDS spending. 2000 , 19, 233-43	11
1850	Helping the urban poor stay with antiretroviral HIV drug therapy. 2000 , 90, 699-701	72

1849	Interaction of Methadone with Didanosine and Stavudine. 2000 , 24, 241-248	30
1848	The role of observational studies in assessing the impact of antiviral therapies. 2000 , 13, 631-635	2
1847	Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. 2000 , 14, F17-23	157
1846	Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. 2000 , 14, 1357-63	75
1845	Evaluating changes in health status in HIV-infected patients: Medical Outcomes Study-HIV and Multidimensional Quality of Life-HIV quality of life questionnaires. Spanish MOS-HIV and MQOL-HIV Validation Group. 2000 , 14, 1439-47	38
1844	Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. 2000 , 14, 1545-52	71
1843	Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. 2000 , 14, 959-69	67
1842	Incidence and predictors of reinfection with <i>Trichomonas vaginalis</i> in HIV-infected women. 2000 , 27, 284-8	46
1841	Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy. 2000 , 19, 618-24	21
1840	CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. 2000 , 14, 173-80	53
1839	Mathematical models of the transmission and control of sexually transmitted diseases. 2000 , 27, 636-43	68
1838	Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. 2000 , 14, 357-66	767
1837	Virological and immunological responses to HAART in asymptomatic therapy-naïve HIV-1-infected subjects according to CD4 cell count. 2000 , 14, 2257-63	33
1836	Protease inhibitor-induced carbamazepine toxicity. 2000 , 23, 216-8	35
1835	Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study. 2000 , 24, 227-231	21
1834	Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. 2000 , 24, 378-85	43
1833	Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy. 2000 , 25, 312-321	188
1832	Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. 2000 , 14, 11-21	114

1831	Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. 2000 , 14, 383-6	92
1830	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. 2000 , 14, 1887-97	56
1829	Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. 2000 , 14, 1899-906	10
1828	The Atlanta Urban Networks Study: a blueprint for endemic transmission. 2000 , 14, 2191-200	49
1827	Psychological effects of HAART: a 2-year study. 2000 , 62, 413-22	64
1826	Phenotypic testing predicts virological response in successive protease inhibitor-based regimens. 2000 , 14, F95-101	19
1825	Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. 2000 , 14, 1731-8	40
1824	Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. 2000 , 14, 1985-91	115
1823	Improving survival following AIDS in Australia, 1991-1996. National HIV Surveillance Committee. 2000 , 14, 2349-54	19
1822	Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. 2000 , 14, 517-24	81
1821	Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 2000 , 40, 127-35	13
1820	A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. 2000 , 1, 13-9	22
1819	Achieving plasma HIV RNA below the level of detection in clinical practice. 2000 , 5, 100-105	
1818	Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. 2000 , 25, 115-23	89
1817	Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. 2000 , 25, 124-9	43
1816	Measuring adherence to antiretroviral medications in clinical trials. 2000 , 1, 36-46	82
1815	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. 2000 , 14, 979-85	67
1814	Differential trends in mortality from AIDS in men and women in Brazil (1984-1995). 2000 , 14, 1269-73	20

1813	Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. 2000 , 14, 2723-30	137
1812	Routine ophthalmologic screening for cytomegalovirus retinitis in patients with AIDS. 2000 , 23, 438-9	5
1811	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. 2000 , 25, 99-102	78
1810	Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial. 2000 , 14, 1961-72	9
1809	The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. 2000 , 14, 405-13	35
1808	Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. 2000 , 14, 2355-60	61
1807	Impact of Zidovudine-Based Triple Combination Therapy on an AIDS Drug Assistance Program. 2000 , 23, 302-313	8
1806	Mortality of HIV-Positive and HIV-Negative Heroin Abusers as a Function of Duration of Injecting Drug Use. 2000 , 23, 332-338	3
1805	Survival in Children With Perinatal HIV Infection and Very Low CD4 Lymphocyte Counts. 2000 , 269-275	
1804	HIV lipodystrophy: a review. 2000 , 1, 37-50	14
1803	Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. 2000 , 14, F63-7	386
1802	Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators. 2000 , 14, 491-7	14
1801	Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPD Peripheral Cytomegalovirus Retinitis Trial. 2000 , 14, 1571-1581	29
1800	Regional differences in presentation of AIDS in Europe. 2000 , 125, 143-51	9
1799	CD4 count/viral load in HIV. 2000 , 42, 79-80	
1798	1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. 2000 , 8, 3-74	0
1797	High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. 2000 , 89, 680-689	54
1796	Science before the CD-ROM. 2000 , 10, 205-6	

1795	Biological synergism between infectious agents. 2000 , 10, 351-3	3
1794	Taking antiretroviral therapy for HIV infection: learning from patients' stories. 2000 , 15, 848-58	54
1793	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 2000 , 1, 76-101	53
1792	Management of protozoal diarrhoea in HIV disease. 2000 , 1, 194-9	15
1791	Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. 2000 , 1, 224-31	81
1790	Economic impact of HIV protease inhibitor therapy in the global use of health-care resources. 2000 , 1, 246-51	9
1789	Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. 2000 , 50, 99-107	137
1788	Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients. 2000 , 120, 107-12	62
1787	Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients. 2000 , 30, 87-94	36
1786	Therapeutic interventions in HIV infection - a critical view. 2000 , 5, A26-31	10
1785	High mortality rates in tuberculosis patients in Zomba Hospital, Malawi, during 32 months of follow-up. 2000 , 94, 305-9	21
1784	Diagnosis and treatment of HIV-associated neurocognitive disorders. 2000 , 2000, 25-35	10
1783	Enhancement of lymphocyte proliferation induced by interleukin-12 and anti-interleukin-10 in HIV-infected patients during highly active antiretroviral therapy. 2000 , 108, 601-7	5
1782	The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. 2000 , 177, 99-111	221
1781	Medical management of HIV-infected patients. 2000 , 23, 78-84	
1780	Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets. 2000 , 8, 2385-98	38
1779	The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. 2000 , 6, 82-5	398
1778	Both a 'magic bullet' and good aim are required to link public health interests and health care needs in HIV infection. 2000 , 6, 261-2	8

1777	Taking aim at HIV replication. 2000 , 6, 735-6	11
1776	Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. 2000 , 6, 757-61	367
1775	Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. 2000 , 6, 762-8	164
1774	Genetic selection for dissociative inhibitors of designated protein-protein interactions. 2000 , 18, 847-51	57
1773	Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. 2000 , 6, 1140-6	158
1772	New targets for inhibitors of HIV-1 replication. 2000 , 1, 40-9	142
1771	Access and use of specific dental services in HIV disease. 2000 , 60, 172-81	18
1770	Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. 2000 , 2, 61-7	44
1769	Protists as opportunistic pathogens: public health impact in the 1990s and beyond. 2000 , 47, 15-20	20
1768	HIV-1 entry - an expanding portal for drug discovery. 2000 , 5, 183-194	65
1767	The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening?. 2000 , 14, 112-36	63
1766	Cytotoxic T lymphocytes in Human Immunodeficiency Virus type-1 infection Important or impotent?. 2000 , 1, 17-36	2
1765	Therapeutic vaccines for the treatment of HIV-1 infection. 2000 , 1, 73-87	2
1764	HIV-associated lipodystrophy syndrome. 2000 , 20, 13-22	39
1763	Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. 2000 , 20, 917-22	19
1762	Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals. 2000 , 20, 151-7	6
1761	Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. 2000 , 20, 727-34	37
1760	Update in internal medicine. 2000 , 31, 329-52	

1759	Reduction in hospitalization costs, morbidity, disability, and mortality in patients with aids treated with protease inhibitors. 2000 , 31, 515-9	28
1758	Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. 2000 , 86, 145-70	62
1757	HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. 2000 , 47, 121-9	134
1756	Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities. 2000 , 48, 143-76	29
1755	Antiretroviral therapy: state of the HAART. 2000 , 45, 1-7	61
1754	Targeting the HIV-protease in AIDS therapy: a current clinical perspective. 2000 , 1477, 189-214	98
1753	Health-related quality of life and virologic outcomes in an HIV clinic. 2000 , 9, 977-85	87
1752	Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy. 2000 , 45, 1301-7	21
1751	A change-point model for reporting delays under change of AIDS case definition. 2000 , 16, 1135-41	4
1750	Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?. 2000 , 16, 919-26	7
1749	Multi-drug resistant HIV-1. 2000 , 41, 5-11	11
1748	Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease. 2000 , 43, 3495-504	65
1747	Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. 2000 , 28, 287-96	21
1746	Healthcare Economics in HIV. 2000 , 2, 371-375	
1745	Diagnosis and Management of Infectious Thyroiditis. 2000 , 2, 147-153	36
1744	The Changing Epidemic of HIV. 2000 , 2, 457-465	3
1743	Treatment strategies for infectious diarrhea in HIV-infected patients. 2000 , 3, 1-6	
1742	Diagnosis and treatment of esophagitis in AIDS. 2000 , 26, 163-8	4

1741	[HIV infection and the eye]. 2000 , 97, 718-36, quiz 735	2
1740	Behandlung gastrointestinaler Infektionen. 2000 , 41, 1302-1317	5
1739	[Infectiology update. II: Diagnosis and therapy]. 2000 , 95, 568-77	1
1738	Has there been a turning point in the numbers of AIDS and HIV antibody positive cases in Ireland?. 2000 , 169, 183-6	
1737	Antiretroviral therapy and declining AIDS mortality in New York City. 2000 , 77, 492-500	19
1736	Palliative care for HIV disease in the era of highly active antiretroviral therapy. 2000 , 77, 150-65	10
1735	Impact of HAART on causes of death of persons with late-stage AIDS. 2000 , 77, 166-75	36
1734	New York City AIDS case mortality rates in the era of potent antiretroviral therapy. 2000 , 77, 255-7	5
1733	Antiretroviral therapy 2000. 2000 , 23, 425-37	4
1732	Anti-retroviral treatment in Nigeria: a review. 2000 , 6, 196-9	
1731	Management of cytomegalovirus retinitis in AIDS. 2000 , 19, 571-84	0
1730	HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. 2000 , 96, 250-258	63
1729	Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. 2000 , 96, 2730-2734	171
1728	HIV resistance testing: value for money. 2000 , 61, 304-5	
1727	Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. 2000 , 160, 3114-20	48
1726	1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 2000 , 8, 5-74	1
1725	Hospitalization due to adverse drug reactions and drug interactions before and after HAART. 2000 , 11, 193-201	5
1724	Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. 2000 , 133, 493-503	91

1723	Discontinuation of chemoprophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators. 2000 , 132, 201-5	33
1722	Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. 2000 , 132, 1011	10
1721	The case for more cautious, patient-focused antiretroviral therapy. 2000 , 132, 306-11	48
1720	Mycobacteriosis in the compromised host. 2000 , 95 Suppl 1, 163-70	2
1719	Estudo temporal das doenças associadas à AIDS no Brasil, 1980-1999. 2000 , 16, S21-S36	25
1718	Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update). 2000 , 5, d30	2
1717	Condom use for preventing the spread of HIV/AIDS: an ethical imperative. 2000 , 93, 453-6	5
1716	Central Nervous System Opportunistic Infections in HIV-1 Infection. 2000 , 5, 43-60	47
1715	Practical approaches to HIV therapy. Recommendations for the year 2000. 2000 , 107, 127-8, 131-6, 138	21
1714	Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. 2000 , 160, 2614-22	146
1713	Pharmacist intervention program for hospitalized patients with HIV infection. 2000 , 57, 2283-4	19
1712	Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. 2000 , 18, 3325-30	84
1711	HIV risk behaviour in gay men: on the rise?. 2000 , 320, 1487-8	25
1710	Hemolytic uremic syndrome in a patient treated with clopidogrel. 2000 , 132, 1006	9
1709	Management of fibromyalgia. 2000 , 132, 1005	1
1708	Isotretinoin in respiratory papillomatosis. 2000 , 132, 1007	9
1707	Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. 2000 , 132, 1009	
1706	Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. 2000 , 284, 183-9	130

1705 HIV Infection in Children: A New Hope. **2000**, 9, 279-294

1704 Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update). **2000**, 5, D30-49

4

1703 Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. **2000**, 284, 2193-202

102

1702 Ethnic and racial differences in long-term survival from hospitalization for HIV infection. **2000**, 11, 163-78

16

1701 Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. **2000**, 162, 64-7

95

1700 Mycoses in AIDS. **2000**, 38, 259-267

19

1699 Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. **2000**, 44, 3213-6

39

1698 High-level resistance to 3'-azido-3'-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. **2000**, 74, 1023-8

37

1697 PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. **2000**, 44, 3150-4

19

1696 Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterin. **2000**, 7, 832-4

18

1695 AIDS related systemic non-Hodgkin's lymphoma. **2000**, 76, 335-41

29

1694 Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. **2000**, 30, 710-8

829

1693 Extract of *Prunella vulgaris* spikes inhibits HIV replication at reverse transcription in vitro and can be absorbed from intestine in vivo. **2000**, 11, 157-64

24

1692 Subacute hypersensitivity pneumonitis in an HIV infected patient receiving antiretroviral therapy. **2000**, 55, 625-7

8

1691 Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. **2000**, 30, 95-9

111

1690 Coronary artery disease and human immunodeficiency virus infection. **2000**, 31, 787-97

104

1689 Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy. **2000**, 31, 805-6

21

1688 Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. **2000**, 95, 3482-9

89

1687	Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. 2000 , 19, 85-94	8
1686	Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy. 2000 , 16, 835-43	8
1685	Pneumocystis carinii pneumonia following discontinuation of primary prophylaxis despite highly active antiretroviral therapy. 2000 , 11, 64-5	2
1684	AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. 2000 , 55, 1194-200	101
1683	The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). 2000 , 181, 1622-8	61
1682	Remission of HIV myelopathy after highly active antiretroviral therapy. 2000 , 54, 267-8	46
1681	The role of transjugular portosystemic shunting in patients with ascites. <i>New England Journal of Medicine</i> , 2000 , 342, 1745-7	59.2 23
1680	Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. 2000 , 34, 1015-21	71
1679	Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. 2000 , 13, 475-498	
1678	Prevalence of nonconvulsive status epilepticus in comatose patients. 2000 , 55, 1421-3	22
1677	Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. 2000 , 284, 190-7	260
1676	Neurocognitive disorders seen in HIV disease. 2000 , 21, 51-70	8
1675	Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. 2000 , 152, 178-85	45
1674	Cerebellar and medullar histoplasmosis. 2000 , 55, 1419	
1673	The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children. 2000 , 182, 88-95	32
1672	Activate your online subscription. 2000 , 55, 1194-1200	104
1671	Discontinuing prophylaxis for opportunistic infection: guiding principles. 2000 , 30 Suppl 1, S66-71	3
1670	Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. 2000 , 181, 358-63	162

1669	A new preadmission staging system for predicting inpatient mortality from HIV-associated <i>Pneumocystis carinii</i> pneumonia in the early highly active antiretroviral therapy (HAART) era. 2000 , 161, 1081-6	40
1668	Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. 2000 , 162, 612-6	108
1667	Antenatal screening for HIV: time to embrace change. 2000 , 9, 908-14	
1666	Management and outcome patterns for adult <i>Pneumocystis carinii</i> pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. 2000 , 118, 704-11	203
1665	Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. 2000 , 14, 2877-87	41
1664	Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. 2000 , 25, 451-8	25
1663	Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. 2000 , 24, 310-5	16
1662	Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. 2000 , 23, 332-8	14
1661	Increasing Proportion of Late Diagnosis of HIV Infection Among Patients With AIDS in Italy Following Introduction of Combination Antiretroviral Therapy. 2000 , 25, 71-76	61
1660	Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. 2000 , 25, 221-8	162
1659	Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study. 2000 , 23, 236-245	79
1658	Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. 2000 , 221-228	37
1657	Effect of Cryopreservation on Measurement of Cytomegalovirus-Specific Cellular Immune Responses in HIV-Infected Patients. 2000 , 25, 109-114	24
1656	Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. 2000 , 14, 659-69	42
1655	Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. 2000 , 24, 115-22	15
1654	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. 2000 , 14, 499-507	390
1653	Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. 2000 , 24, 182-8	24
1652	Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. 2000 , 11, 496-501	55

1651	The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. 2000 , 117, 1128-45	93
1650	Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 2000, 1, 9-16	12
1649	Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. 2000 , 14, 2559-66	49
1648	Why does Pneumocystis carinii pneumonia still occur?. 2000 , 14, 2611-2	4
1647	Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. 2000 , 24, 270-4	40
1646	Absence of Association Between Individual Thymidine Analogues or Nonnucleoside Analogues and Lipid Abnormalities in HIV-1 Infected Persons on Initial Therapy. 2000 , 24, 310-315	21
1645	Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000. 2000 , 1, 60-110	20
1644	Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. 2000 , 14, 397-403	165
1643	Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. 2000 , 14, 1409-12	21
1642	Routine Ophthalmologic Screening for Cytomegalovirus Retinitis in Patients With AIDS. 2000 , 23, 438-439	4
1641	Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. 2000 , 14, 761-70	75
1640	Interaction of Methadone with Didanosine and Stavudine. 2000 , 24, 241-248	51
1639	Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. 2000 , 14, 839-44	66
1638	New Treatment Protocol Including Lympholytic and Antiretroviral Drugs to Inhibit Murine AIDS. 2000 , 23, 107-113	3
1637	Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. 2000 , 25, 99-102	51
1636	Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. 2000 , 25, 322-8	7
1635	Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. 2000 , 14, 59-67	42
1634	Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. 2000 , 14, 1163-70	75

1633	Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. 2000 , 14, 1935-42		55
1632	Outcome of a Second-Line Protease Inhibitor-Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy. 2000 , 24, 115-122		25
1631	Estimating the National Cost of Treating People With HIV Disease: Patient, Payer, and Provider Data. 2000 , 24, 182-188		24
1630	Incidence and Trends in Kaposi's Sarcoma in the Era of Effective Antiretroviral Therapy. 2000 , 24, 270-274		86
1629	New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS. 2000 , 23, 107-13		7
1628	Potential Interventions for HIV/AIDS Wasting: An Overview. 2000 , 25, S74-S80		16
1627	Eradication of Cryptosporidia and Microsporidia Following Successful Antiretroviral Therapy. 2000 , 25, 124-129		87
1626	Efavirenz in HIV infection. <i>New England Journal of Medicine</i> , 2000 , 342, 1290-1	59.2	0
1625	Carotid endarterectomy revisited. <i>New England Journal of Medicine</i> , 2000 , 342, 1743-5	59.2	24
1624	Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. 2000 , 30 Suppl 2, S151-9		91
1623	Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beinr Community Programs for Clinical Research on AIDS. <i>New England Journal of Medicine</i> , 2000 , 342, 1085-92	59.2	117
1622	Cancer and herbs. <i>New England Journal of Medicine</i> , 2000 , 342, 1742-3	59.2	98
1621	Ethical considerations in the treatment of infertility in women with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 2000 , 342, 1748-50	59.2	53
1620	Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. 2000 , 55, 1419-20		2
1619	Therapeutic developments in cytomegalovirus retinitis. 2000 , 9, 207-20		17
1618	Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. 2000 , 160, 1134-40		42
1617	Controversies in neurological infectious diseases. 2000 , 20, 375-86		16
1616	Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. 2000 , 30 Suppl 1, S5-14		500

1615	Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. 2000 , 16, 559-67	88
1614	Nelfinavir mesylate. 2000 , 1, 1429-40	22
1613	Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. 2000 , 95, 457-62	92
1612	Salvage therapy for HIV infection: when and how. 2000 , 14, 465-76	4
1611	Antiretroviral medication adherence and persistence with respect to adherence tool usage. 2000 , 14, 351-8	21
1610	Treatment of HIV disease in the new millennium. 2000 , 12, 140-4	4
1609	Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. 2000 , 16, 1031-7	12
1608	Monitoring patients with HIV disease. 2000 , 53, 266-72	19
1607	Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 2000 , 283, 653-7	63
1606	Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. 2000 , 160, 2050-6	331
1605	Progressive multifocal leucoencephalopathy: progress in the AIDS era. 2000 , 69, 569-71	17
1604	Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. 2000 , 182, 435-41	60
1603	Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. 2000 , 182, 1658-63	47
1602	The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. 2000 , 182, 1077-83	94
1601	Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. 2000 , 182, 330-3	58
1600	Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. 2000 , 31, 1253-7	96
1599	Construction and characterization of murine cytomegaloviruses that contain transposon insertions at open reading frames m09 and M83. 2000 , 74, 7411-21	21
1598	A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. 2000 , 31, 1245-52	52

1597	The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. 2000 , 182, 744-50	18
1596	Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. 2000 , 31, 987-94	16
1595	The human immunodeficiency virus-infected traveler. 2000 , 31, 1403-8	31
1594	Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli. 2000 , 97, 5812-7	67
1593	Antiretroviral prescribing patterns in the Texas prison system. 2000 , 31, 1476-81	27
1592	Is cytomegalovirus viraemia a useful tool in managing CMV disease?. 2000 , 76, 342-4	3
1591	Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. 2000 , 152, 923-33	58
1590	Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 2000 , 342, 1416-29	59.2 189
1589	Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type 1-infected patients: the changes in opportunistic prophylaxis study. 2000 , 181, 1635-42	92
1588	Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. 2000 , 74, 10269-73	63
1587	Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. 2000 , 182, 611-5	41
1586	The tolerability of efavirenz after nevirapine-related adverse events. 2000 , 31, 806-7	18
1585	Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy. 2000 , 55, 1424	8
1584	Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. 2000 , 162, 393-8	73
1583	Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. 2000 , 283, 381-90	791
1582	Prevention of perinatal HIV transmission during pregnancy. 2000 , 46, 657-68	47
1581	Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. 2000 , 31, 803-5	221
1580	Stereotactic biopsy of cerebral lesions in AIDS. 2000 , 30, 491-9	48

1579	Strategies for long-term success in the treatment of HIV infection. 2000 , 283, 1329-34	78
1578	1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. 2000 , 30 Suppl 1, S29-65	35
1577	Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. 2000 , 30, 313-8	74
1576	Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. 2000 , 133, 401-10	284
1575	Immune restoration with antiretroviral therapies: implications for clinical management. 2000 , 284, 223-8	109
1574	Sulfa or sulfone prophylaxis and geographic region predict mutations in the <i>Pneumocystis carinii</i> dihydropteroate synthase gene. 2000 , 182, 1192-8	122
1573	Introduction: Therapeutic Issues in the Management of Patients Infected with the Human Immunodeficiency Virus (HIV). 2000 , 13, 422-425	
1572	A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. 2000 , 44, 1132-9	23
1571	HIV-1 protease: maturation, enzyme specificity, and drug resistance. 2000 , 49, 111-46	60
1570	Incidence of cervical squamous intraepithelial lesions in HIV-infected women. 2000 , 283, 1031-7	337
1569	Resistance profiles in patients with viral rebound on potent antiretroviral therapy. 2000 , 181, 1143-7	27
1568	Management of HIV-1 Infection in Adults and Adolescents. 2000 , 13, 426-441	1
1567	Interleukin 2 treatment for HIV infection. 2000 , 284, 236-8	5
1566	An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. 2000 , 30 Suppl 1, S15-28	9
1565	Long-term patient adherence to antiretroviral therapy. 2000 , 34, 703-9	65
1564	A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. 2000 , 44, 920-8	550
1563	Is interruption of HIV therapy always harmful?. 2000 , 45, 137-8	6
1562	In vitro activity of human immunodeficiency virus protease inhibitors against <i>Pneumocystis carinii</i> . 2000 , 181, 1629-34	37

1561	Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. 2000 , 11, 291-301	31
1560	HTLV-1 and HIV infections of the central nervous system in tropical areas. 2000 , 68, 550-7	13
1559	Progressive stroke in an HIV-1-positive patient under protease inhibitors. 2000 , 44, 252-4	11
1558	Infections with <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium avium</i> among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. 2000 , 162, 865-72	94
1557	Recurrence of <i>Mycobacterium avium</i> infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. 2000 , 30, 511-4	49
1556	Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. 2000 , 30, 779-83	73
1555	Prophylaxis for opportunistic infections in an era of effective antiretroviral therapy. 2000 , 31, 597-601	11
1554	Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose zidovudine in human immunodeficiency virus-negative adults. 2000 , 44, 2672-8	83
1553	Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. 2000 , 7, 352-9	102
1552	Antiretroviral Resistance: Mechanisms, Detection and Clinical Implications. 2000 , 13, 442-456	1
1551	Immune-Based Therapies for the Management of HIV Infection: Highly Active Antiretroviral Therapy and Beyond. 2000 , 13, 515-532	
1550	Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. 2000 , 269, 641-6	49
1549	Glycyrrhizin improves the resistance of MAIDS mice to opportunistic infection of <i>Candida albicans</i> through the modulation of MAIDS-associated type 2 T cell responses. 2000 , 95, 145-55	21
1548	Looking behind: time for anal cancer screening. 2000 , 108, 674-5	4
1547	Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. 2000 , 129, 634-9	136
1546	Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. 2000 , 130, 49-56	92
1545	The ophthalmologist and the global impact of the AIDS epidemic LV Edward Jackson Memorial Lecture. 2000 , 129, 1-8	19
1544	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. 2000 , 22, 549-72	44

1543	Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. 2000 , 22, 911-36; discussion 898	165
1542	Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. 2000 , 22, 685-708	489
1541	Les multiples aspects de la r�sistance du VIH aux antir�troviraux. 2000 , 30, 551-564	1
1540	Usefulness of the BACTEC MYCO/F lytic system for detection of mycobacteremia in a clinical microbiology laboratory. 2000 , 40, 63-6	3
1539	Acute tubulointerstitial nephritis attributable to indinavir therapy. 2000 , 35, E16	27
1538	Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. 2000 , 35, 884-8	93
1537	Dermatophyte infections in human immune deficiency virus (HIV) disease. 2000 , 43, S135-42	30
1536	Global epidemiology of HIV infection and AIDS. 2000 , 18, 381-7	5
1535	Competing risk adjustment reduces overestimation of opportunistic infection rates in AIDS. 2000 , 53, 817-22	13
1534	Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. 2000 , 3, 508-14	50
1533	Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. 2000 , 36, 574-80	62
1532	The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. 2000 , 11, 37-44	60
1531	Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. 2000 , 89, 299-304	203
1530	New developments in the etiopathogenesis and treatment of HIV-related Kaposi's sarcoma. 2000 , 18, 469-77	5
1529	Update on highly active antiretroviral therapy: progress and strategies. 2000 , 54, 7-12	23
1528	Residual HIV-1 replication. 2000 , 54, 13-5	3
1527	Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. 2000 , 37, 18-23	23
1526	Hit HIV-1 hard, but only when necessary. 2000 , 355, 2147-52	89

1525	AIDS across Europe, 1994-98: the EuroSIDA study. 2000 , 356, 291-6	380
1524	Health locus of control, distress, and utilization of protease inhibitors among HIV-positive men. 2000 , 49, 157-62	23
1523	Reconstitution immune sous HAART: Effet des traitements antirétroviraux combinés. 2000 , 11, 39-47	
1522	Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART. 2000 , 17, 5-11	7
1521	Preventing AIDS but not HIV-1 infection with a DNA vaccine. 2000 , 290, 463-5	17
1520	[Trends in the number of human immunodeficiency virus infected persons and AIDS cases in Spain: 1980-1998]. 2000 , 115, 85-9	24
1519	Antiretroviral therapy in the year 2000. 2000 , 14, 827-49	7
1518	Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. 2000 , 115, 118	1
1517	6-Aminoquinolones as new potential anti-HIV agents. 2000 , 43, 3799-802	94
1516	Quality-of-Care Indicators for HIV/AIDS. 2000 , 7, 315-330	7
1515	Vigilancia epidemiológica del sida en España. Situación a 30 de junio de 2000. 2000 , 26, 557-561	
1514	Significant Drug Interactions in the HIV Patient. 2000 , 13, 499-514	1
1513	Les traitements antirétroviraux. 2000 , 11, 23-37	
1512	Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing. 2000 , 14, 879-99	5
1511	Les antirétroviraux utilisés en multithérapie. 2000 , 11, 13-22	
1510	Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). 2000 , 12, 255-66	1152
1509	Cost effectiveness of combination HIV therapy: 3 years later. 2000 , 17, 325-30	46
1508	Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers. 2000 , 18, 355-68	8

1507	HIV-1 drug resistance genotyping. A review of clinical and economic issues. 2000 , 18, 425-33	15
1506	Management Strategies for Herpesvirus Infections of the CNS. 2000 , 14, 95-113	1
1505	The changing pattern of mental health problems in HIV infection: the view from London, UK. 2000 , 12, 333-41	23
1504	Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. 2000 , 26, 195-205	85
1503	Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. 2000 , 32, 111-23	94
1502	Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource-poor countries. 2000 , 14, 251-7	10
1501	A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection. 2000 , 16, 1809-20	7
1500	Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. 2000 , 14, 155-68	105
1499	Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. 2000 , 14, 13-8	34
1498	Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. 2000 , 30, 231-3	125
1497	HIV-1 protease inhibitors. 2000 , 30 Suppl 2, S160-70	51
1496	El período de incubación del sida en España antes de la terapia antirretroviral de alta eficacia. 2000 , 115, 681-686	4
1495	[Cancer and human immunodeficiency virus in the era of combination therapy]. 2000 , 115, 93-4	1
1494	[New criteria for the prophylaxis of infective diseases in patients infected by HIV]. 2000 , 200, 218-22	
1493	Opportunistic infections and other clinical manifestations of HIV disease in children. 2000 , 47, 79-108	34
1492	Traitements antirétroviraux: Les checks immunologiques. 2000 , 11, 75-83	
1491	Natural history of HIV-1 infection. 2000 , 14, 809-25, v-vi	55
1490	Cambios asistenciales en las consultas urgentes de los pacientes infectados por el virus de la inmunodeficiencia humana desde la generalización de los inhibidores de las proteasas. 2000 , 115, 132-134	2

1489	Prophylaxis of opportunistic infections. 2000 , 14, 929-44	4
1488	Eficacia del tratamiento antirretroviral en pacientes con infecci3n por el virus de la inmunodeficiencia humana. Estudio de 807 pacientes. 2000 , 115, 481-486	5
1487	[Effect of antiretroviral treatment and prophylaxis for opportunistic infections on survival of patients with AIDS]. 2000 , 200, 187-92	2
1486	The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm ³ . 2000 , 95, 3142-6	73
1485	Primary care of the patient with HIV/AIDS. 2000 , 14, 967-81	1
1484	HIV and AIDS in inpatient dermatology. Approach to the consultation. 2000 , 18, 509-20, x	5
1483	Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. 2000 , 16, 429-34	44
1482	A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection. 2000 , 22, 19-31	11
1481	Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?. 2000 , 23, 57-76	75
1480	Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?. 2000 , 23, 467-81	77
1479	Nelfinavir: an update on its use in HIV infection. 2000 , 59, 581-620	100
1478	Abacavir: a review of its clinical potential in patients with HIV infection. 2000 , 60, 447-79	112
1477	Delavirdine: a review of its use in HIV infection. 2000 , 60, 1411-44	69
1476	Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. 2000 , 95, 457-462	36
1475	Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?. 2000 , 14, 627-35	96
1474	Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. 2000 , 14, 901-28	38
1473	Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. 2000 , 18, 665-708	438
1472	Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling. 2001 , 17, 147-59	19

1471	Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management. 2001 , 120, 607-21	39
1470	Mother-to-child transmission of drug-resistant HIV. 2001 , 4, 29-37	9
1469	New therapeutic modalities for benign oesophageal disease: an overview. 2001 , 33, 260-5	3
1468	The cost effectiveness of combination antiretroviral therapy for HIV disease. <i>New England Journal of Medicine</i> , 2001 , 344, 824-31	59.2 388
1467	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. 2001 , 44, 1866-82	69
1466	Lipodystrophy syndrome in patients with HIV infection: quality of life issues. 2001 , 24, 157-66	64
1465	Human immunodeficiency virus and assisted reproduction: reconsidering evidence, reframing ethics. 2001 , 75, 843-58	59
1464	Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. <i>New England Journal of Medicine</i> , 2001 , 345, 398-407	59.2 103
1463	Heat shock proteins: novel therapeutic tools for HIV-infection?. 2001 , 1, 67-77	32
1462	Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. 2001 , 164, 2120-6	78
1461	[Opportunistic infections and highly active antiretroviral therapy]. 2001 , 116, 56-7	2
1460	[Opportunistic episodes in patients infected with the human immunodeficiency virus during the first 6 months of HAART]. 2001 , 117, 81-4	5
1459	Vigilancia epidemiológica del sida en España. Situación a 31 de diciembre de 2000. 2001 , 27, 482-485	
1458	SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. 2001 , 98, 12718-23	303
1457	Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. 2001 , 98, 658-663	286
1456	Opportunistic infections in HIV disease: down but not out. 2001 , 15, 433-55	15
1455	Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. <i>New England Journal of Medicine</i> , 2001 , 345, 1522-8	59.2 409
1454	Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities. 2001 , 282, 595-601	49

1453	The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. 2001 , 131, 457-67	63
1452	Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. 2001 , 132, 700-10	41
1451	Approaches to gene therapy for human immunodeficiency virus infection. 2001 , 12, 1013-9	39
1450	AIDS--the first 20 years. <i>New England Journal of Medicine</i> , 2001 , 344, 1764-72	59.2 287
1449	Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures. 2001 , 99, 222-31	15
1448	Disease severity and symptoms of depression in Black Americans infected with HIV. 2001 , 14, 3-10	18
1447	Effect of acquired immune deficiency syndrome wasting on the protein metabolic response to acute exercise. 2001 , 50, 288-92	5
1446	[Current antiretroviral therapy]. 2001 , 22, 42-52	2
1445	HIV-1 integrase: the next target for AIDS therapy?. 2001 , 49, 237-46	42
1444	[Epidemiological features and incidence trends of primary cerebral lymphomas observed in 80 HIV-infected patients from 1983 to 1999]. 2001 , 49, 572-5	
1443	[Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results]. 2001 , 49, 559-66	3
1442	Therapeutic drug monitoring of anti-HIV drugs. 2001 , 1220, 145-160	1
1441	A randomized comparative trial of testosterone and protein supplements for weight loss in HIV+ men. 2001 , 21, 159-169	1
1440	"Natural history" clinical trials: an enduring contribution to modern medical practice. 2001 , 56, 1-12	1
1439	Discovery and clinical development of HIV-1 protease inhibitors. 2001 , 56, 213-51	17
1438	Kaposi's sarcoma. 2001 , 19, 269-83	14
1437	Knowledge of partner risk and secondary transmission of HIV. 2001 , 20, 277-81	11
1436	Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. 2001 , 55, 7-15	29

1435	Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimen. 2001 , 55, 16-22	2
1434	Current review and clinical management of patients with primary HIV-1 infection: limits and perspectives. 2001 , 55, 301-7	7
1433	Predictors of protease inhibitor-associated adverse events. 2001 , 55, 321-3	13
1432	The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations. 2001 , 55, 295-300	7
1431	Therapy naive in the era of potent antiretroviral therapy. 2001 , 54, 149-56	14
1430	General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. 2001 , 54 Suppl 1, S22-8	102
1429	Human immunodeficiency virus infection, aging, and cancer. 2001 , 54 Suppl 1, S29-34	34
1428	Development and validation of a self-completed HIV symptom index. 2001 , 54 Suppl 1, S77-90	314
1427	Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. 2001 , 22, 241-7	61
1426	Does plasma HIV RNA predict outcome in a cohort of treated HIV-infected individuals followed over 3 years?. 2001 , 22, 271-8	3
1425	Immunomodulators as adjunctive therapy for HIV-1 infection. 2001 , 22, 289-95	23
1424	Impact of HAART on the clinical management of AIDS-related cancers. 2001 , 37, 1320-4	43
1423	Epidemiology of AIDS-related tumours in developed and developing countries. 2001 , 37, 1188-201	101
1422	Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. 2001 , 37, 1306-15	47
1421	The status of HIV/AIDS nursing in Australia: a specialty in decline?. 2001 , 12, 52-60	0
1420	Treatment of anemia in patients with HIV infection, Part 1: The need for adequate guidelines. 2001 , 12, 39-51	6
1419	Solid organ transplantation in HIV-infected individuals: obstacles and opportunities. 2001 , 33, 1310-4	18
1418	Solid organ transplantation in HIV-positive patients. 2001 , 33, 3646-8	27

1417	Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. 2001 , 357, 432-5	151
1416	Community-based approaches to HIV treatment in resource-poor settings. 2001 , 358, 404-9	379
1415	[Treatment of lipodystrophy in patients with human immunodeficiency virus infection]. 2001 , 116, 469-75	1
1414	[Reduction of hematogenous infection in HIV positive patients following highly active antiretroviral therapy]. 2001 , 116, 256-8	
1413	[Paronychia in patients infected with HIV treated with indinavir]. 2001 , 201, 455-8	1
1412	Diarrhea and malabsorption in the elderly. 2001 , 30, 427-44	43
1411	Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. 2001 , 76, 1171-5	38
1410	[Management of chronic hepatitis C infection in patients infected with the human immunodeficiency virus: from what we know to what we ignore]. 2001 , 116, 775-8	1
1409	Lipodistrofia y alteraciones metabólicas en pacientes infectados por el virus de la inmunodeficiencia humana tratados con inhibidores de la proteasa. 2001 , 13, 254-259	0
1408	[Treatment of opportunistic infections among adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active anti-retroviral therapy]. 2001 , 19, 376-92	6
1407	[Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy]. 2001 , 117, 607-10	7
1406	Osteonecrosis bilateral de caderas, corticoides e inhibidores de la proteasa del virus de la inmunodeficiencia humana. 2001 , 19, 34-35	0
1405	Infectious diarrhea in human immunodeficiency virus. 2001 , 30, 637-64	27
1404	[Causes of mortality among patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy]. 2001 , 19, 85-6	8
1403	[Risk factors related to infections during the first year of highly active antiretroviral therapy]. 2001 , 116, 41-6	2
1402	[Antiretroviral drug resistance]. 2001 , 19, 287-90	1
1401	Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. 2001 , 17, 1635-43	41
1400	Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. 2001 , 33, 306-11	12

1399	Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. 2001 , 19, 95-104	14
1398	Efavirenz: a pharmacoeconomic review of its use in HIV infection. 2001 , 19, 421-36	18
1397	Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS. 2001 , 19, 535-50	6
1396	An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. 2001 , 17, 873-86	19
1395	Lopinavir/Ritonavir (Kaletra). 2001 , 17, 35-36	0
1394	Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. 2001 , 17, 93-8	17
1393	An investigation of why eligible patients do not receive HAART. 2001 , 15, 185-91	59
1392	Changing patterns of "hospital-at-home" care use by persons with AIDS in the era of combination antiretroviral therapy. 2001 , 15, 625-32	1
1391	AIDS--past and future. <i>New England Journal of Medicine</i> , 2001 , 344, 1788-91	59.2 29
1390	Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. 2001 , 17, 1223-9	15
1389	Ongoing trials of immune-based therapies for HIV infection in adults. 2001 , 1, 413-24	4
1388	Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). 2001 , 41, 105-16	34
1387	Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. 2001 , 13, 733-41	30
1386	Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. 2001 , 33, 1747-55	102
1385	Effect of Insurance on Mortality in an HIV-Positive Population in Care. 2001 , 96, 883-894	92
1384	Lack of change in the distribution of AIDS-defining opportunistic diseases and the related degree of immunodeficiency during the periods before and after the introduction of highly active antiretroviral therapy. 2001 , 20, 410-3	13
1383	. 2001 ,	
1382	Treatment of hyperlipidemia in HIV-infected patients. 2001 , 58, 607-14	12

1381 New Perspectives in Antiretroviral Therapy of HIV Infection. 423-437

1380 Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. **2001**, 56, 355-61

55

1379 The changing epidemiology of HIV infection: new challenges for HIV palliative care. **2001**, 94, 442-8

21

1378 Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. **2001**, 135, 557-65

127

1377 Analysis of the ~~AT~~ T-Cell Receptor Repertoire in HIV Infection. 127-146

1376 Management Guidelines for the HCV and HIV Co-Infected Adult: Recommendations of a Multidisciplinary Expert Panel. **2001**, 12, 8A-21A

1375 Management of Antiretroviral-Related Neuropsychiatrics Adverse Effects. **2001**, 12, 7C-8C

1374 HIV in the United States at the turn of the century: an epidemic in transition. **2001**, 91, 1060-8

323

1373 Treatment of CMV retinitis with intravitreal ganciclovir in the HAART era. **2001**, 12, 300-4

2

1372 Health care utilization among homeless adults prior to death. **2001**, 12, 50-8

55

1371 Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. **2001**, 280, E549-53

39

1370 Evaluation of viral resistance to reverse transcriptase inhibitors (RTI) in HIV-1-infected patients before and after 6 months of single or double antiretroviral therapy. **2001**, 5, 177-82

2

1369 Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. **2001**, 19, 2171-8

229

1368 HIV and AIDS: an overview. **2001**, 15, 45-52; quiz 54-5

1367 Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. **2001**, 91, 1464-73

19

1366 Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. **2001**, 15, 369-78

179

1365 Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naïve individuals. **2001**, 15, 2379-84

36

1364 HIV disease among immigrants coming to Italy from outside of the European Union: a case-control study of epidemiological and clinical features. **2001**, 127, 527-33

16

1363	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor Experienced Patients With HIV-Associated Lipodystrophy. 2001 , 27, 229-236	55
1362	Importance of mental health assessment in HIV-infected outpatients. 2001 , 28, 240-9	36
1361	Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. 2001 , 27, 143-52	40
1360	The care of HIV-infected adults in rural areas of the United States. 2001 , 28, 385-92	53
1359	Access and activism: the ethics of providing antiretroviral therapy in developing countries. 2001 , 15 Suppl 5, S81-90	14
1358	Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. 2001 , 15, 1115-23	137
1357	Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. 2001 , 15, 1603-12	81
1356	Structural normalization of the lymphoid tissue in asymptomatic HIV-infected patients after 48 weeks of potent antiretroviral therapy. 2001 , 15, 2371-8	5
1355	Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy. 2001 , 15, 195-200	66
1354	Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. 2001 , 15, 341-5	90
1353	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. 2001 , 15, 1483-91	157
1352	Two long terminal repeat circles and persistent HIV-1 replication. 2001 , 14, 5-11	17
1351	Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. 2001 , 15, 61-9	57
1350	Discontinuation of primary prophylaxis in HIV-infected patients at high risk of <i>Pneumocystis carinii</i> pneumonia: prospective multicentre study. 2001 , 15, 501-7	20
1349	Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. 2001 , 15, 693-701	101
1348	Molecular detection of respiratory syncytial virus in postmortem lung tissue samples from Mexican children deceased with pneumonia. 2001 , 20, 495-501	26
1347	Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. 2001 , 15, 1389-98	322
1346	Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. 2001 , 15, 2149-55	65

1345	Pediatric HIV infection. 2001 , 44, 243-75	7
1344	Sexual and reproductive behavior of women with HIV infection. 2001 , 44, 289-99	8
1343	Primary Care of the HIV-Infected Patient. 2001 , 4, 142-153	
1342	Adherence to HIV regimens: 10 vital lessons. 2001 , 101, 37-43; quiz 44	10
1341	Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. 2001 , 15, 1201-11	31
1340	The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. 2001 , 29, 548-56	51
1339	Pleural effusions and pneumothoraces in AIDS. 2001 , 7, 202-9	22
1338	Atovaquone suspension for treatment of <i>Pneumocystis carinii</i> pneumonia in HIV-infected patients. 2001 , 15, 211-4	29
1337	Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. 2001 , 15, 1369-77	283
1336	Pharmacokinetic and other drug interactions in patients with AIDS. 2001 , 23, 591-605	42
1335	Antiretroviral therapy-associated hyperlipidaemia in HIV disease. 2001 , 12, 313-9	67
1334	Hyperlipidemia and inhibitors of HIV protease. 2001 , 4, 99-103	21
1333	HIV and drug allergy. 2001 , 1, 311-316	71
1332	Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naïve persons with high and low baseline viral loads. 2001 , 2, 317-22	11
1331	Health-related quality of life in individuals infected with HIV in the era of HAART. 2001 , 2, 484-92	58
1330	HIV Care in Correctional Settings Is Cost-Effective and Improves Medical Outcomes. 2001 , 10, S9-S15	7
1329	Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. 2001 , 27, 168-75	53
1328	Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. 2001 , 27, 459-62	13

1327	Potential Adverse Effects of Structured Therapeutic Interruptions on the Pool of HIV-Infected Cells. 2001 , 28, 197-199	
1326	Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. 2001 , 15, 591-9	16
1325	Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. 2001 , 15, 1493-502	70
1324	Pulmonary Infiltrates in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era in Spain. 2001 , 27, 35-43	15
1323	Efavirenz as a Substitute for Protease Inhibitors in HIV-1 Infected Patients With Undetectable Plasma Viral Load on HAART: A Median Follow-Up of 64 Weeks. 2001 , 27, 459-462	17
1322	Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study. 2001 , 28, 73-80	23
1321	Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells. 2001 , 28, 197-8	1
1320	Lymphoid tissue viral burden and duration of viral suppression in plasma. 2001 , 15, 1477-82	15
1319	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. 2001 , 15, 201-9	41
1318	Risk factors for and trends in gonorrhea incidence among persons infected with HIV in the United States. 2001 , 15, 1149-55	32
1317	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. 2001 , 15, F1-9	175
1316	Should physicians withhold highly active antiretroviral therapies from HIV-AIDS patients who are thought to be poorly adherent to treatment?. 2001 , 15, 153-9	18
1315	The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. 2001 , 15, 2157-64	134
1314	International perspectives on antiretroviral resistance. Resistance to protease inhibitors. 2001 , 26 Suppl 1, S34-50	43
1313	Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections. 2001 , 27, 44-48	8
1312	Genotypic drug resistance and cause of death in HIV-infected persons who died in 1999. 2001 , 28, 250-3	3
1311	Progression to AIDS or death as endpoints in HIV clinical trials. 2001 , 2, 330-5	5
1310	Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. 2001 , 41, 386-96	19

1309	Association between steatorrhea, growth, and immunologic status in children with perinatally acquired HIV infection. 2001 , 155, 149-53	6
1308	Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study. 2001 , 2, 399-407	8
1307	Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study. 2001 , 2, 438-44	18
1306	Improving participation in HIV clinical trials: impact of a brief intervention. 2001 , 2, 205-12	20
1305	Penile cancer and human papilloma virus (HPV) in a human immunodeficiency virus (HIV)-infected patient. 2001 , 19, 266-72	22
1304	Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. 2001 , 27, 318-20	25
1303	Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. 2001 , 2, 429-37	35
1302	Clinical Cohort Study: HOPS Data. 2001 , 10, S2-S4	
1301	Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. 2001 , 2, 160-70	16
1300	Two cases of long lasting bacteremia due to Mycobacterium avium complex despite new macrolides-containing regimens in patients with acquired immunodeficiency syndrome. 2001 , 40, 454-8	2
1299	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. 2001 , 26, 159-163	55
1298	Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy. 2001 , 97, 214-20	9
1297	Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. 2001 , 98, 3406-12	242
1296	Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. 2001 , 98, 1078-85	108
1295	Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. 2001 , 17, 87-93	33
1294	Human Immunodeficiency Virus Infection in Elderly Patients. 2001 , 94, 397-400	1
1293	Characteristics of Individuals Infected With the Human Immunodeficiency Virus and Provider Interaction in the Predominantly Rural Southeast. 2001 , 94, 212-222	1
1292	Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. 2001 , 28, 309-12	17

1291	Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. 2001 , 15, 23-31	69
1290	Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. 2001 , 15, 1985-91	48
1289	Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. 2001 , 15, 1749-56	181
1288	Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. 2001 , 15, 2293-301	21
1287	Pneumocystis carinii pneumonia in pregnancy. 2001 , 120, 666-71	37
1286	Location, race, and hospital care for AIDS patients: an analysis of 10 states. 2001 , 38, 319-30	13
1285	Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients. 2001 , 26, 332-9	8
1284	Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. 2001 , 27, 49-55	1
1283	Infections in HIV disease. 2001 , 1, 292-5	1
1282	The Effect of New Drugs on Mortality from Rare Diseases and HIV. 2001 ,	2
1281	Antiviral drug development and the impact of drug resistance. 2001 , 311-340	
1280	Deciding where and how to be tested for HIV: what matters most?. 2001 , 27, 292-300	25
1279	HIV in the late 1990s: what we don't know may hurt us. 2001 , 91, 1016-7	29
1278	Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. 2001 , 91, 1474-81	20
1277	Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue. 2001 , 26, 1-7	29
1276	The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. 2001 , 27, 124-9	4
1275	Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy. 2001 , 26, 326-331	21
1274	Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 Infection. 2001 , 27, 251-259	160

1273	Pneumocystis carinii Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis. 2001 , 26, 151-158	10
1272	Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. 2001 , 26, 326-31	62
1271	Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. 2001 , 27, 229-36	113
1270	Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. 2001 , 26, 159-63	28
1269	Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. 2001 , 161, 441-6	140
1268	HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. 2001 , 27, 321-30	21
1267	Resistance to antiretroviral therapy among patients in Uganda. 2001 , 26, 495-500	23
1266	Comparison of Virologic, Immunologic, and Clinical Response to Five Different Initial Protease Inhibitor-Containing and Nevirapine-Containing Regimens. 2001 , 27, 350-364	9
1265	Mortality in a Cohort of HIV-Infected Adults Started on a Protease Inhibitor-Containing Therapy. 2001 , 26, 480-482	13
1264	Resistance to Antiretroviral Therapy Among Patients in Uganda. 2001 , 26, 495-500	22
1263	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. 2001 , 27, 49-55	3
1262	Increase and Plateau of CD4 T-Cell Counts in the 3 Years After Initiation of Potent Antiretroviral Therapy. 2001 , 27, 168-175	76
1261	Condom Use Consistency Associated With Beliefs Regarding HIV Disease Transmission Among Women Receiving HIV Antiretroviral Therapy. 2001 , 27, 289-291	7
1260	Deciding Where and How to Be Tested for HIV: What Matters Most?. 2001 , 27, 292-300	30
1259	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. 2001 , 27, 321-330	31
1258	Trust and the acceptance of and adherence to antiretroviral therapy. 2001 , 28, 47-58	307
1257	Trends in immunologic and clinical status of newly diagnosed HIV-positive patients initiating care in the HAART era. 2001 , 28, 270-2	12
1256	[HIV-lipodystrophy syndrome]. 2001 , 96, 391-401	3

1255	Immune Reconstitution Strategies in HIV. 2001 , 3, 302-308	6
1254	Therapy and Prevention of Cytomegalovirus Retinitis. 2001 , 3, 371-377	1
1253	Risk-taking in the Era of Highly Active Antiretroviral Therapy. 2001 , 3, 101-102	2
1252	Changing patterns in the etiology of HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. 2001 , 20, 71-3	10
1251	Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. 2001 , 20, 202-5	33
1250	Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4 + T-cell counts. 2001 , 20, 253-9	7
1249	Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. 2001 , 160, 611-6	20
1248	Rubber band ligation for hemorrhoidal disease can be safely performed in select HIV-positive patients. 2001 , 44, 1079-82	20
1247	Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. 2001 , 757, 325-32	41
1246	High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. 2001 , 764, 363-84	31
1245	Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients. 2001 , 15, 1627-32	9
1244	The role of therapeutic drug monitoring in treatment of HIV infection. 2001 , 51, 301-8	48
1243	Effects of recombinant granulocyte-colony stimulating factor administration during Mycobacterium avium infection in mice. 2001 , 124, 239-47	4
1242	Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. 2001 , 16, 850-859	44
1241	Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. 2001 , 16, 360-8	60
1240	Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. 2001 , 16, 625-33	137
1239	Anti-retroviral therapy, insulin resistance and lipodystrophy. 2001 , 3, 67-71	21
1238	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 2001 , 2, 276-313	91

1237	Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. 2001 , 2, 43-51	14
1236	Combined therapy with saquinavir, zidovudine and zalcitabine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naïve patients. 2001 , 2, 35-42	2
1235	Assessing the cost-effectiveness of HAART for adults with HIV in England. 2001 , 2, 52-8	35
1234	A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. 2001 , 2, 78-83	23
1233	Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management. 2001 , 2, 123-32	32
1232	Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. 2001 , 2, 189-94	14
1231	Candidate vaccines for immunotherapy in HIV. 2001 , 2, 260-5	7
1230	Cytomegalovirus infection: the point in 2001. 2001 , 2, 255-9	12
1229	Dermatological immune restoration syndrome: does it exist?. 2001 , 15, 430-2	28
1228	1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. 2001 , 11, 1437-40	54
1227	Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy. 2001 , 6, 212-8	8
1226	The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. 2001 , 27, 326-35	140
1225	Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies. 2001 , 20, 2489-504	3
1224	Respiratory diseases in the first year of life in children born to HIV-1-infected women. 2001 , 31, 267-76	18
1223	Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. 2001 , 64, 35-41	12
1222	Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. 2001 , 91, 155-63	149
1221	Germ cell tumors in patients infected by the human immunodeficiency virus. 2001 , 92, 1460-7	16
1220	Trends in non-Hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States. 2001 , 66, 159-66	20

1219	Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. 2001 , 66, 229-40	74
1218	Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. 2001 , 15, 43-6	15
1217	[Good, but adverse effect-producing drugs. The importance of HIV protease inhibitors in combination therapy]. 2001 , 30, 217-20	
1216	[Characterization of resistance in HIV. Comparison of geno- and phenotypic resistance to HIV-1 protease inhibitors]. 2001 , 30, 228-32	
1215	[Just expensive or also cost effective? Pharmacoeconomic aspects of HIV therapy]. 2001 , 30, 248-52	
1214	Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy. 2001 , 34, 519-29	16
1213	Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. 2001 , 45, 1225-30	108
1212	Pharmacology and clinical experience with saquinavir. 2001 , 2, 303-15	4
1211	Prospects for gene therapy using HIV-based vectors. 2001 , 26, 159-74	9
1210	Prescription of and Adherence to Antiretroviral Therapy Among Women with AIDS. 2001 , 5, 371-378	22
1209	Social Factors Related to Antiretroviral Therapy Use in Injection Drug Users. 2001 , 5, 363-369	4
1208	The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece. 2001 , 25, 73-80	7
1207	QSAR study and VolSurf characterization of anti-HIV quinolone library. 2001 , 15, 203-17	15
1206	Pain in patients with HIV infection: issues for the new millennium. 2001 , 5 Suppl A, 43-8	10
1205	Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. 2001 , 34, 283-7	307
1204	The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. 2001 , 34, 1193-9	247
1203	The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. 2001 , 42, 134-9	132
1202	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. 2001 , 7, 323-8	56

1201	Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings. 2001 , 20, 711-7	31
1200	Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. 2001 , 79, 63-76	31
1199	Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. 2001 , 7, 712-8	132
1198	The pharmacogenomics of HIV therapy. 2001 , 1, 243-53	29
1197	Drugs and cardiotoxicity in HIV and AIDS. 2001 , 946, 179-99	49
1196	Risk of HIV and other blood-borne infections in the cardiac setting: patient-to-provider and provider-to-patient transmission. 2001 , 946, 291-309	20
1195	Predicting the unpredictable: transmission of drug-resistant HIV. 2001 , 7, 1016-20	178
1194	Cardiology and AIDS--HAART and the consequences. 2001 , 946, 130-44	22
1193	Cardiovascular disease risk factors in HIV-infected patients in the HAART era. 2001 , 946, 200-13	18
1192	HIV chemotherapy. 2001 , 410, 995-1001	431
1191	A highly prevalent polymorphism at codon 72 of HIV-1 reverse transcriptase in Argentina prevents hybridization reaction at codon 74 in the LiPA genotyping test. 2001 , 94, 87-95	6
1190	Metabolic complications associated with antiretroviral therapy. 2001 , 51, 151-77	122
1189	The relationship of pregnancy to the use of highly active antiretroviral therapy. 2001 , 184, 1221-7	26
1188	The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. 2001 , 21, 41-51	104
1187	Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. 2001 , 13, 155-67	31
1186	Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor. 2001 , 17, 414-5	11
1185	Transplantation in the HIV+ patient. 2001 , 1, 13-7	63
1184	Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. 2001 , 183, 401-8	27

1183	A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. 2001 , 32, 623-32	64
1182	Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. 2001 , 184, 127-35	36
1181	Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus. 2001 , 184, 256-67	25
1180	Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy. 2001 , 184, 1341-4	19
1179	Comparative analysis of human cytomegalovirus-specific CD4(+) T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients. 2001 , 8, 1225-30	4
1178	Murine cytomegalovirus open reading frame M27 plays an important role in growth and virulence in mice. 2001 , 75, 1697-707	32
1177	Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. 2001 , 183, 1682-7	39
1176	Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. 2001 , 33, 700-5	138
1175	Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues. 2001 , 33, 873-84	11
1174	Analysis of dynamic cohort data. 2001 , 154, 366-72	10
1173	Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. 2001 , 33, 466-72	43
1172	The impact of state policy on the costs of HIV infection. 2001 , 58, 31-53; discussion 54-9	16
1171	Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends. 2001 , 32, 955-62	114
1170	Evaluation of chronic hepatitis B virus (HBV) infection in coinfecting patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. 2001 , 32, 963-9	70
1169	Coding Changes and Apparent HIV/AIDS Mortality Trends in Florida, 1999. 2001 , 286, 1839	5
1168	Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. 2001 , 75, 8195-202	110
1167	Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. 2001 , 184, 201-5	19
1166	Highly active antiretroviral therapy responders exhibit a phenotypic lymphocyte pattern comparable to that of long-term nonprogressors. 2001 , 126, 248-56	7

1165	AIDS and the lung in a changing world. 2001 , 56, 423-6	7
1164	Glucose disorders associated with HIV and its drug therapy. 2001 , 35, 343-51	34
1163	Metabolic syndromes in human immunodeficiency virus infection. 2001 , 55 Suppl 1, 36-41	7
1162	Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. 2001 , 32, 783-93	25
1161	HIV infection in women in the United States: status at the Millennium. 2001 , 285, 1186-92	188
1160	A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. 2001 , 33, 2055-60	26
1159	CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. 2001 , 85, 837-41	5
1158	Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5). 2001 , 45, 495-501	78
1157	A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection. 2001 , 47, 353-5	0
1156	Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. 2001 , 15, 143-52	191
1155	Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. 2001 , 15, 347-55	132
1154	Open-Label Phase II Trial of Amprenavir, Abacavir, and Fixed-Dose Zidovudine/Lamivudine in Newly and Chronically HIV-1 Infected Patients. 2001 , 26, 332-339	8
1153	High Prevalence of Genotypic and Phenotypic HIV-1 Drug-Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'Ivoire. 2001 , 26, 501-506	32
1152	Hospitalization Rates in an Urban Cohort After the Introduction of Highly Active Antiretroviral Therapy. 2001 , 27, 143-152	65
1151	Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. 2001 , 27, 350-64	23
1150	Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART. 2001 , 28, 320-31	23
1149	Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. 2001 , 15, 1359-68	23
1148	A prospective study of discontinuing primary and secondary <i>Pneumocystis carinii</i> pneumonia prophylaxis after CD4 cell count increase to > 200 x 10 ⁶ /l. 2001 , 15, 1509-15	21

1147	Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. 2001 , 80, 54-73	166
1146	Health Care Resource Utilization in the Johns Hopkins HIV Clinic Cohort. 2001 , 10, S5-S8	
1145	Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. 2001 , 28, 114-23	22
1144	Patterns of adherence with antiretroviral medications: an examination of between-medication differences. 2001 , 28, 259-63	28
1143	Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals. 2001 , 2, 6-16	13
1142	The role of immunotherapy in the treatment of HIV. 2001 , 15 Suppl 2, S1-3	1
1141	HIV-protease inhibitors alter retinoic acid synthesis. 2001 , 15, 1979-84	29
1140	Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. 2001 , 27, 35-43	42
1139	Prevalence of resistance mutations in antiretroviral-naïve chronically HIV-infected patients in 1998: a French nationwide study. 2001 , 15, 1777-82	31
1138	Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis. 2001 , 26, 151-8	6
1137	Low Prevalence of Cardiac Abnormalities in an HIV-Seropositive Population on Antiretroviral Combination Therapy. 2001 , 27, 318-320	25
1136	Alternative strategies for anti-HIV treatment. 2001 , 15 Suppl 5, S161-9	3
1135	Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. 2001 , 15, 1679-86	29
1134	Access to antiretroviral therapy in HIV-infected injection drug users. 2001 , 15, 1727-8	6
1133	High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. 2001 , 26, 501-6	83
1132	Impact of HIV infection on mortality in a cohort of injection drug users. 2001 , 28, 351-7	118
1131	High-dose cytosine-arabioside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. 2001 , 28, 416-21	35
1130	Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. 2001 , 15, 609-15	30

1129	Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. 2001 , 26, 44-55	33
1128	Resistance to Protease Inhibitors. 2001 , 26, S34-S50	40
1127	Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. 2001 , 28, 345-50	33
1126	Brief report: condom use consistency associated with beliefs regarding HIV disease transmission among women receiving HIV antiretroviral therapy. 2001 , 27, 289-91	13
1125	Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. 2001 , 30, 864-71	49
1124	Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. 2001 , 15, 675-81	87
1123	The Effect of Nevirapine in Combination With Nelfinavir in Heavily Pretreated HIV-1 Infected Patients. 2001 , 27, 124-129	6
1122	Endobronchial <i>Pneumocystis carinii</i> Pneumonia. 2001 , 8, 197-199	
1121	Rationing HIV Medications: What Do Patients and the Public Think About Allocation Policies?. 2001 , 26, 56-62	5
1120	Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART. 2001 , 28, 114-123	78
1119	Rationing HIV medications: what do patients and the public think about allocation policies?. 2001 , 26, 56-62	5
1118	Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?. 2001 , 15 Suppl 2, S36-42	18
1117	Virologic and Immunologic Effect of Antiretroviral Therapy on HIV-1 in Gut-Associated Lymphoid Tissue. 2001 , 26, 1-7	38
1116	Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. 2001 , 26, 480-2	26
1115	Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. 2001 , 15, 185-94	150
1114	The impact of highly active antiretroviral therapy on HIV-specific immune function. 2001 , 15 Suppl 2, S4-10	12
1113	Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. 2001 , 15, 1009-18	60
1112	Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. 2001 , 27, 44-8	9

1111	Pilot Study of a Combination of Highly Active Antiretroviral Therapy and Cytokines to Induce HIV-1 Remission. 2001 , 26, 44-55	35
1110	Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. 2001 , 27, 251-9	274
1109	Endobronchial Pneumocystis carinii Pneumonia. 2001 , 8, 197-199	
1108	Burkitt's lymphoma shortly after an acute HIV infection, treated with highly active retroviral treatment. 2001 , 56, 321-2	1
1107	Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. 2001 , 2, 339-45	42
1106	Adherence to combination antiretroviral treatment in children. 2001 , 2, 466-73	23
1105	Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile. 2001 , 13, 569-74	7
1104	Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. 2001 , 2, 113-21	10
1103	Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. 2001 , 2, 227-306	21
1102	Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. 2001 , 17, 1467-71	171
1101	Eligibility policies for the state AIDS drug assistance programs. 2001 , 32, 81-104	3
1100	Antiviral Treatments. 2001 , 316-341	
1099	The changing incidence of four AIDS-related malignancies in a large urban center. 2001 , 15, 405-6	4
1098	Infection with GB virus C and reduced mortality among HIV-infected patients. <i>New England Journal of Medicine</i> , 2001 , 345, 715-24	59.2 341
1097	Use of complementary and alternative therapies in HIV-infected patients. 2001 , 15, 159-67	94
1096	Effect of HCV viral dynamics on treatment design: lessons learned from HIV. 2001 , 96, 2818-28	9
1095	Factors associated with delays in accessing HIV primary care in rural Arkansas. 2001 , 15, 527-32	26
1094	Quality of life among urban Canadian HIV/AIDS clinic outpatients. 2001 , 12, 505-12	52

1093	Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. 2001 , 45, 3445-50		117
1092	Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. 2001 , 98, 597-602		34
1091	The hemophilias--from royal genes to gene therapy. <i>New England Journal of Medicine</i> , 2001 , 344, 1773-9	59.2	747
1090	Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. 2001 , 32, 1487-93		122
1089	Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. 2001 , 33, 240-7		273
1088	Tuberculosis, HIV and the developing world. 2001 , 1, 62-8		10
1087	Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. 2001 , 285, 1592-601		66
1086	HIV in cervical cancer. 2001 , 12, 283-5		7
1085	Discontinuation of secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. <i>New England Journal of Medicine</i> , 2001 , 344, 168-74	59.2	127
1084	Infections with <i>Ehrlichia chaffeensis</i> and <i>Ehrlichia ewingii</i> in persons coinfecting with human immunodeficiency virus. 2001 , 33, 1586-94		126
1083	Factors affecting adherence and convenience in antiretroviral therapy. 2001 , 12 Suppl 4, 18-24		10
1082	Psychosocial factors are associated with prolonged hospitalization in a population with advanced HIV. 2001 , 12, 302-6		10
1081	Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naïve patients treated with protease inhibitor-based therapy. 2001 , 184, 983-91		99
1080	Diagnosis and monitoring of human cytomegalovirus diseases in patients with human immunodeficiency virus infection by use of a real-time PCR assay. 2001 , 33, 1756-61		18
1079	Prognostic score of short-term survival in HIV-infected patients admitted to medical intensive care units. 2001 , 12, 239-44		14
1078	A case of pneumocystis pneumonia after cessation of secondary prophylaxis. 2001 , 12, 126-7		5
1077	Changing patterns of presentations of patients with HIV-related disease at a tertiary referral centre and its implications for physician training. 2001 , 12, 453-9		6
1076	Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naïve patients. 2001 , 183, 579-88		28

1075	Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. 2001 , 184, 707-12	34
1074	Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. 2001 , 183, 1285-9	103
1073	Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. 2001 , 32, 464-8	20
1072	Immune interventions. 2001 , 58, 187-203	3
1071	Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. 2001 , 32, 633-5	31
1070	Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. 2001 , 33, 1938-43	59
1069	Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. 2001 , 184, 547-51	151
1068	HIV associated nephropathy: a treatable condition. 2001 , 77, 97-100	8
1067	Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. 2001 , 32, 1207-14	109
1066	Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. 2001 , 32, 1738-55	23
1065	Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. 2001 , 45, 3663-8	19
1064	The metabolic toxicities of antiretroviral therapy. 2001 , 12, 555-62; quiz 563-4	65
1063	Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. 2001 , 45, 1438-43	21
1062	Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens. 2001 , 77, 449-52	
1061	Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. 2001 , 33, 1417-23	494
1060	Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfecting with human immunodeficiency virus-1. 2001 , 33, 2049-54	5
1059	Nutrition in the era of highly active antiretroviral therapy. 2001 , 32, 1769-75	37
1058	Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. 2001 , 108, E72	52

1057	Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. 2001 , 33, 344-8	11
1056	Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. 2001 , 75, 1301-11	91
1055	Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. 2001 , 32, 794-800	176
1054	Liver fibrosis progression is related to CD4 cell depletion in patients coinfecting with hepatitis C virus and human immunodeficiency virus. 2001 , 183, 134-7	187
1053	Analysis of sputum in COPD. 2001 , 56, 420-2	8
1052	Genetic diversity of <i>Pneumocystis carinii</i> isolated from human immunodeficiency virus-positive patients in Turin, Italy. 2001 , 39, 2995-8	10
1051	The risk of myocardial infarction in HIV-infected patients receiving HAART: a case report. 2001 , 12, 612-3	5
1050	Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution. 2001 , 12, 573-81	26
1049	Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. 2001 , 184, 1386-91	25
1048	The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. 2001 , 268, 2085-95	33
1047	Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus. 2001 , 8, 579-84	4
1046	Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. 2001 , 183, 730-5	38
1045	Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2. 2001 , 32, 766-73	26
1044	Discontinuing anticytomegalovirus therapy in patients with cytomegalovirus retinitis and AIDS. 2001 , 85, 381-2	1
1043	Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. 2001 , 33, 1579-85	45
1042	Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. 2001 , 32, 492-7	831
1041	Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. 2001 , 12, 659-64	10
1040	Effects of virologic rebound on CD4 cell counts. 2001 , 32, 1231-2	10

1039	Recurrences of cytomegalovirus retinitis in a human immunodeficiency virus-infected patient, despite potent antiretroviral therapy and apparent immune reconstitution. 2001 , 32, 815-9		72
1038	Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. 2001 , 45, 236-42		59
1037	The AIDS drug assistance programs and coverage of HIV-related medications. 2001 , 35, 155-66		8
1036	Cd4+ T cells programmed to traffic to lymph nodes account for increases in numbers of cd4+ T cells up to 1 year after the initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection. 2001 , 184, 93-7		9
1035	Immunrekonstitutionssyndrom. 2001 , 126, 44-44		
1034	The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. 2001 , 86, 3480-7		106
1033	Strategies for treating HIV-related lipodystrophy. 2001 , 10, 1443-56		13
1032	Dendritic cell ontogeny as an aetiological factor in respiratory tract diseases in early life. 2001 , 56, 419-20		15
1031	A randomized trial of the discontinuation of primary and secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. <i>New England Journal of Medicine</i> , 2001 , 344, 159-67	59.2	176
1030	AIDS among heterosexuals in surveillance reports. <i>New England Journal of Medicine</i> , 2001 , 344, 611-3	59.2	7
1029	Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. <i>New England Journal of Medicine</i> , 2001 , 344, 817-23	59.2	243
1028	Providing antiretroviral therapy for HIV infection. <i>New England Journal of Medicine</i> , 2001 , 344, 844-6	59.2	20
1027	Antiretroviral therapy for previously treated patients. <i>New England Journal of Medicine</i> , 2001 , 345, 452-5	59.2	24
1026	GB virus C and mortality from HIV infection. <i>New England Journal of Medicine</i> , 2001 , 345, 761-2	59.2	14
1025	The changing face of pediatric HIV-1 infection. <i>New England Journal of Medicine</i> , 2001 , 345, 1568-9	59.2	19
1024	Preimplantation genetic diagnosis by comparative genomic hybridization. <i>New England Journal of Medicine</i> , 2001 , 345, 1569-71	59.2	8
1023	Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. 2001 , 32, 1756-68		32
1022	Reproductive function in human immunodeficiency virus infection. 2001 , 86, 2338-43		41

1021	[Immune reconstitution syndrome. A new disease in HIV-infected patients effectively treated with antiretroviral drugs]. 2001 , 126, 1017-22	0
1020	Gesundheitsökonomische Aspekte der HIV-Infektion. 2001 , 6, 89-94	
1019	[Diagnosis of resistance in the treatment of AIDS: clarification of viral and cellular factors]. 2001 , 126, 1249-54	
1018	The architecture of the corneal stroma. 2001 , 85, 379-81	84
1017	Immune restoration syndrome manifested by pulmonary sarcoidosis. 2001 , 177, 1427	17
1016	6-oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro. 2001 , 20, 481-6	3
1015	Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. 2001 , 15, 193-9	69
1014	Use of Complementary and Alternative Therapies in Patients with HIV. 2001 , 7, 371-379	
1013	The evolving mode of presentation of HIV-infected patients to health services of northern Spain: 1985 through December 1999. 2001 , 15, 67-71	1
1012	HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. 2001 , 15, 411-23	48
1011	Toward a definition of HIV expertise: a survey of experienced HIV physicians. 2001 , 15, 321-30	14
1010	Dually eligible individuals with AIDS: characteristics and health services use. 2001 , 14, 19-35	9
1009	Clinical care issues for women living with HIV and AIDS in the United States. 2001 , 17, 1-33	13
1008	Critical issues of HIV treatment in the era of highly active antiretroviral therapy. 2001 , 10, 175-83	2
1007	Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence. 2002 , 13, 748-54	21
1006	Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. 2002 , 16, 327-35	30
1005	Physician-patient relationships, patient satisfaction, and antiretroviral medication Adherence among HIV-infected adults attending a public health clinic. 2002 , 16, 43-50	187
1004	AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. 2002 , 16, 107-12	11

1003	Increasing CD4+ T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy. 2002 , 18, 969-75	17
1002	Human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy: denial of poor medication adherence or recalcitrant infection?. 2002 , 16, 355-9	3
1001	Does access to health care impact survival time after diagnosis of AIDS?. 2002 , 16, 223-31	13
1000	Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. 2002 , 185, 188-95	68
999	Mediators of social support and antiretroviral adherence among an indigent population in New York City. 2002 , 16, 431-9	102
998	The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. 2002 , 18, 685-93	170
997	Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS. 2002 , 18, 1395-406	27
996	Lung Cancer. 2002 ,	
995	Alcohol use and HIV pharmacotherapy. 2002 , 18, 757-70	57
994	Vacuolar myelopathy and vacuolar cerebellar leukoencephalopathy: a late complication of AIDS after highly active antiretroviral therapy-induced immune reconstitution. 2002 , 16, 579-84	16
993	Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?. 2002 , 16, 527-35	47
992	Characterization of nef gene of HIV type 1 in highly active antiretroviral therapy treated AIDS patients with discordance between viral load and CD4+ T cell counts. 2002 , 18, 983-7	7
991	Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. 2002 , 34, 1002-7	29
990	Decreasing AIDS mortality rates among young adults in the city of Florence, 1987-1999. 2002 , 56, 399; author reply 399-400	3
989	Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy. 2002 , 46, 1928-33	1
988	Solid-organ transplantation in HIV-infected patients. <i>New England Journal of Medicine</i> , 2002 , 347, 284-7 59.2	105
987	Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. 2002 , 76, 707-16	262
986	Pneumocystis Carinii Pneumonia in Adult Non-HIV Disorders. 2002 , 17, 283-301	6

985	Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. 2002 , 99, 13377-8	14
984	AIDS-related systemic non-Hodgkin's lymphoma at a large community program. 2002 , 18, 237-42	28
983	HIV-1 drug resistance: can we overcome?. 2002 , 2, 751-61	33
982	Infectious Complications in Children with Cancer and Children with Human Immunodeficiency Virus Infection. 2002 , 441-464	1
981	Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. 2002 , 18, 501-6	44
980	Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. 2002 , 18, 95-102	26
979	Initiation of HAART in drug-naïve HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. 2002 , 18, 419-26	20
978	Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. 2002 , 169, 5347-57	88
977	Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial). 2002 , 46, 1906-13	19
976	Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. 2002 , 46, 909-12	33
975	Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. 2002 , 46, 2926-32	103
974	Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?. 2002 , 99, 4-6	35
973	Mothers living with HIV/AIDS: mental, physical, and family functioning. 2002 , 14, 633-44	74
972	Imaging of the central nervous system in HIV infection. 2002 , 14, 48-59	11
971	Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. 2002 , 18, 1011-9	18
970	Quality of life assessment in HIV-positive persons: application and validation of the WHOQOL-HIV, Italian version. 2002 , 14, 405-15	30
969	Combination genetic therapy to inhibit HIV-1. 2002 , 5, 33-41	24
968	HCV chronic hepatitis in patients with HIV: clinical management issues. 2002 , 97, 1598-606	20

967	Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. 2002 , 46, 746-54	47
966	Measuring Substantive AIDS Policies in the American States. 2002 , 34, 45-50	
965	Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. 2002 , 185 Suppl 2, S128-37	29
964	Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. 2002 , 186, 189-97	48
963	Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. 2002 , 186, 851-4	49
962	Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma. 2002 , 46, 3684-5	2
961	Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. 2002 , 40, 762-7	42
960	Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. 2002 , 94, 718-32	13
959	Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens. 2002 , 186, 1155-60	107
958	Nonadherence to highly active antiretroviral therapy: clinically relevant patient categorization based on electronic event monitoring. 2002 , 18, 327-30	22
957	Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. 2002 , 166, 262-7	110
956	Chemotherapeutika-Resistenz und neue Virusvarianten bei sexuell Übertragbaren Infektionen/Chemotherapeutic Resistance and Novel Virus Variants in Sexually Transmitted Infections. 2002 , 26, 474-485	
955	Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. 2002 , 34, 1108-14	134
954	Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. 2002 , 56, 153-9	60
953	Coreceptor usage and biological phenotypes of HIV-1 isolates. 2002 , 40, 911-7	3
952	Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. 2002 , 156, 211-8	42
951	A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. 2002 , 13, 231-40	16
950	Indinavir induces acute and reversible peripheral insulin resistance in rats. 2002 , 51, 937-42	85

949	Interactions between recreational drugs and antiretroviral agents. 2002 , 36, 1598-613	97
948	Hospitalization in HIV in Chicago. 2002 , 1, 26-33	12
947	Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. 2002 , 288, 222-35	519
946	Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. 2002 , 46, 3075-9	29
945	Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors. 2002 , 59, 812-8	46
944	Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. 2002 , 78, 255-60	14
943	Chlamydia screening and sexual health. 2002 , 78, 396-7	25
942	Acute coronary syndrome in patients with human immunodeficiency virus disease. 2002 , 53, 545-9	5
941	Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?. 2002 , 1, 95-103	9
940	Hyperlipidemia in HIV-positive patients receiving antiretrovirals. 2002 , 36, 592-5	9
939	To work or not to work: combination therapies and HIV. 2002 , 12, 1353-72	17
938	Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. 2002 , 3, 27-35	82
937	Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. 2002 , 31, 536-41	33
936	Laboratory Monitoring in the Management of HIV Infection. 2002 , 33, 193-202	
935	Prophylaxis of opportunistic infections in HIV-infected adults in sub-Saharan Africa: opportunities and obstacles. 2002 , 16, 1309-17	7
934	The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. 2002 , 16 Suppl 4, S61-8	35
933	Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. 2002 , 16, 605-13	240
932	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. 2002 , 16, 1039-44	86

931	Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. 2002 , 29, 356-62	48
930	Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. 2002 , 29, 388-95	93
929	Chronic disease self-management and adherence to HIV medications. 2002 , 31 Suppl 3, S163-6	86
928	The importance of routine HIV testing in the incarcerated population: the Rhode Island experience. 2002 , 14, 45-52	56
927	TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. 2002 , 16, 2013-8	80
926	Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1 Infected Women and Prevention of Perinatal HIV-1 Transmission. 2002 , 29, 484-494	505
925	In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. 2002 , 30, 369-78	18
924	Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. 2002 , 16, 1051-8	306
923	Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. 2002 , 29, 244-53	112
922	Long-term exposure to lifelong therapies. 2002 , 29 Suppl 1, S28-40	86
921	Impact of Suppression of Viral Replication by Highly Active Antiretroviral Therapy on Immune Function and Phenotype in Chronic HIV-1 Infection. 2002 , 30, 33-40	4
920	Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. 2002 , 30, 364-6	14
919	No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. 2002 , 31, 137-46	13
918	Evaluation of a non-name-based HIV reporting system in San Francisco. 2002 , 29, 504-10	1
917	Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. 2002 , 17, 436-41	15
916	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. 2002 , 31, 951-8	54
915	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. 2002 , 16, 1009-17	86
914	Addressing the challenges of adherence. 2002 , 29 Suppl 1, S2-10	220

913	Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. 2002 , 162, 2125-32	174
912	Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. 2002 , 3, 279-86	91
911	Technologies for measuring HIV-1 drug resistance. 2002 , 3, 227-36	5
910	Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. 2002 , 324, 757	56
909	Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. 2002 , 3, 52-7	63
908	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). 2002 , 16, 369-79	154
907	Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. 2002 , 283, H2363-70	41
906	Infection in the Organ Transplant Recipient. 2002 , 573-679	26
905	Paracardial lipodystrophy versus pericardial effusion in HIV positive patients. 2002 , 87, E4	1
904	Fumagillin for intestinal microsporidiosis. <i>New England Journal of Medicine</i> , 2002 , 347, 1381; author reply 1381	59.2 1
903	Hepatitis C and progression of HIV disease. 2002 , 288, 199-206	323
902	Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. 2002 , 76, 2206-16	78
901	Prevention interventions for HIV positive individuals. 2002 , 78, 393-5	15
900	Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. 2002 , 13, 683-90	31
899	Antiretroviral therapeutics. 2002 , 8 Suppl 2, 148-50	1
898	Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. 2002 , 185, 1409-16	31
897	High risk sexual behaviours among heroin sniffers who have no history of injection drug use: implications for HIV risk reduction. 2002 , 14, 391-8	35
896	Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. 2002 , 35, 1520-6	31

895	Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. 2002 , 155, 760-70	43
894	Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. 2002 , 41, 192-6	12
893	Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. 2002 , 185, 861-7	47
892	Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. 2002 , 185, 290-8	25
891	Quantitative structure-activity relationship study of 2-arylsulfonyl-6-substituted benzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. 2002 , 17, 219-25	3
890	Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. 2002 , 13, 706-13	32
889	Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. 2002 , 59, 1944-50	379
888	Intracellular accumulation of human immunodeficiency virus protease inhibitors. 2002 , 46, 3228-35	64
887	Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. 2002 , 34, 91-7	84
886	A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. 2002 , 34, 277-84	115
885	Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. 2002 , 34, 677-85	42
884	Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. 2002 , 110, e56	61
883	Reply. 2002 , 34, 557-558	
882	Pharmacokinetics of saquinavir co-administered with cimetidine. 2002 , 50, 1081-4	18
881	Does patient sex affect human immunodeficiency virus levels?. 2002 , 35, 313-22	128
880	The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. 2002 , 43, 1458-63	33
879	Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. 2002 , 35, 1250-7	102
878	A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. 2002 , 185, 178-87	108

877	HIV associated thrombotic microangiopathy. 2002 , 78, 520-5	26
876	Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. 2002 , 34, 543-6	135
875	Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-hepatitis C virus coinfection. 2002 , 35, 1527-33	8
874	Kaletra (lopinavir/ritonavir). 2002 , 36, 1193-203	83
873	Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy. 2002 , 35, E8-E13	38
872	Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. 2002 , 13, 1889-93	115
871	Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. 2002 , 35, 1238-43	65
870	Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy. 2002 , 35, e37-9	11
869	. 2002 , 56, 400-400	78
868	Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. 2002 , 185, 599-607	155
867	Long-term outcomes among antiretroviral-naïve human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. 2002 , 35, 1005-9	77
866	Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. 2002 , 186, 1092-7	63
865	Commentary: meta-analysis of individual participants' data in genetic epidemiology. 2002 , 156, 204-10	77
864	Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. 2002 , 49, 515-24	41
863	Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. 2002 , 34, 558-9	24
862	Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features. 2002 , 40, 837-45	40
861	Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. 2002 , 34, 662-7	33
860	Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. 2002 , 186, 1403-11	115

859	Introduction: the importance of identifying and treating complications of human immunodeficiency virus disease. 2002 , 185 Suppl 2, S103-4	
858	Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. 2002 , 34, 394-7	24
857	The curtain call. 2002 , 78, 392-392	78
856	Mycobacterium avium genes expressed during growth in human macrophages detected by selective capture of transcribed sequences (SCOTS). 2002 , 70, 3714-26	76
855	Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. 2002 , 34, 529-34	92
854	Patients with HIV infection and fever: a diagnostic approach. 2002 , 57, 184-90	10
853	Can patient self-management help explain the SES health gradient?. 2002 , 99, 10929-34	341
852	Randomized, Open-Label Study of the Impact of Two Doses of Subcutaneous Recombinant Interleukin-2 on Viral Burden in Patients With HIV-1 Infection and CD4+ Cell Counts of B00/mm3: CPCRA 059. 2002 , 29, 221-231	23
851	Genotypic HIV-1 Drug Resistance Testing in Antiretroviral-Naive Subjects in Houston, Texas. 2002 , 29, 317-319	2
850	Prevalence and Correlates of Highly Active Antiretroviral Therapy Switching in the Women's Interagency HIV Study. 2002 , 29, 495-503	16
849	Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. 2002 , 29, 484-94	666
848	Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy. 2002 , 29, 546-7	3
847	Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. 2002 , 30, 21-6	57
846	Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. 2002 , 30, 271-7	98
845	Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. 2002 , 30, 278-87	67
844	Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. 2002 , 31 Suppl 3, S112-7	91
843	Survival rates in NYC in the era of combination ART. 2002 , 30, 111-8	49
842	Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. 2002 , 29, 495-503	22

841	Unrecognized HIV infection among patients attending sexually transmitted disease clinics. 2002 , 92, 280-3	52
840	Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinics. 2002 , 30, 351-8	21
839	Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. 2002 , 31, 257-75	293
838	Predictive value of HIV-1 viral load on risk for opportunistic infection. 2002 , 30, 154-8	24
837	Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. 2002 , 30, 191-5	38
836	Genotypic HIV-1 drug resistance testing in antiretroviral-naïve subjects in Houston, Texas. 2002 , 29, 317-9	4
835	Hospital and Outpatient Health Services Utilization Among HIV-Infected Patients in Care in 1999. 2002 , 21-26	
834	Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. 2002 , 30, 33-40	31
833	Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. 2002 , 29, 378-87	200
832	Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990-1999. 2002 , 31, 339-47	61
831	Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. 2002 , 92, 388-94	290
830	Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. 2002 , 162, 2478-86	54
829	Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. 2002 , 137, 734-7	23
828	HIV-infected persons' knowledge of their sexual partners' HIV status. 2002 , 14, 183-9	31
827	Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection. 2002 ,	1
826	Neurologic and psychiatric complications of antiretroviral agents. 2002 , 16, 1201-15	72
825	HIV drug interactions: the good, the bad, and the other. 2002 , 24, 26-31	24
824	Risk behaviour and sexually transmitted diseases are on the rise in gay men, but what is happening with HIV?. 2002 , 15, 37-41	27

823	Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. 2002 , 81, 213-27	405
822	Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. 2002 , 16, 47-52	15
821	Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy. 2002 , 21, 388-92	17
820	Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. 2002 , 24, 302-9	24
819	The pharmacokinetics of nelfinavir in HIV-1-infected children. 2002 , 24, 487-91	13
818	Liver transplantation for HIV-infected patients with end-stage liver disease. 2002 , 7, 114-123	5
817	Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen. 2002 , 21, 435-8	20
816	Prevalence of visual symptoms among patients with newly diagnosed cytomegalovirus retinitis. 2002 , 22, 278-82	23
815	The Washington state "name-to-code" HIV reporting system: a public health perspective. 2002 , 8, 1-14	2
814	Recent trends in the epidemiology of invasive mycoses. 2002 , 15, 569-74	154
813	Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. 2002 , 16, 1587-94	33
812	Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. 2002 , 16, 39-45	34
811	Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. 2002 , 16, 1019-29	124
810	Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. 2002 , 16, 1609-16	42
809	Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. 2002 , 16, 1663-71	211
808	Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. 2002 , 16, 2027-34	58
807	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l. 2002 , 16, 1371-81	80
806	Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. 2002 , 16, 1945-51	161

805	Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. 2002 , 16, 2183-93	139
804	Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users. 2002 , 129, 325-33	7
803	Regional and temporal changes in AIDS in Europe before HAART. 2002 , 129, 565-76	4
802	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. 2002 , 16, 551-60	114
801	To stop or not to stop: that is the question, but what is the answer?. 2002 , 16, 787-9	10
800	HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. 2002 , 16, 877-87	27
799	Symptom management in people with AIDS. 2002 , 102, 48-56; quiz 57	32
798	Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. 2002 , 16, 727-36	161
797	Supernatants of HIV-infected immune cells affect the barrier function of human HT-29/B6 intestinal epithelial cells. 2002 , 16, 983-91	48
796	High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. 2002 , 16, 993-1001	64
795	Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. 2002 , 16, 1859-66	155
794	T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. 2002 , 16, 2137-43	80
793	State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. 2002 , 40, 429-41	21
792	Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. 2002 , 16, 1139-46	90
791	HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. 2002 , 57, 191-201	16
790	Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers. 2002 , 14, 189-93	
789	Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. 2002 , 3, 9-16	14
788	The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. 2002 , 3, 263-71	12

787	Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. 2002 , 3, 371-8	72
786	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000. 2002 , 3, 99-114	16
785	Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. 2002 , 3, 324-32	12
784	Differential characteristics of HIV-infected penitentiary patients and HIV-infected community patients. 2002 , 3, 139-47	3
783	Reactivation of CMV retinitis after treatment with subtenon corticosteroids for immune recovery uveitis in a patient with AIDS. 2002 , 34, 780-2	23
782	Acute myeloid leukemia in patients infected with HIV-1. 2002 , 16, 865-76	25
781	Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. 2002 , 29, 117-21	149
780	Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. 2002 , 30, 478-84	53
779	Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. 2002 , 3, 451-61	27
778	Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. 2002 , 29, 197-202	56
777	Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm ³ : CPCRA 059. 2002 , 29, 221-31	33
776	Gender difference in HIV RNA levels: a meta-analysis of published studies. 2002 , 31, 11-9	92
775	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. 2002 , 16, 53-61	80
774	Supervised interruptions of antiretroviral therapy. 2002 , 16 Suppl 4, S157-69	14
773	Challenges in delivering antiretroviral treatment in resource poor countries. 2002 , 16 Suppl 4, S177-87	12
772	"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. 2002 , 30, 159-66	30
771	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. 2002 , 16, 747-55	36
770	Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. 2002 , 16, 1617-26	100

769	Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. 2002 , 99, 590-9	56
768	Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. 2002 , 162, 1973-80	45
767	HIV Infection and its Implications for Palliative Care in South Africa. 2002 , 10, 168-171	1
766	Physical condition and activity of daily living among HIV patients infected through blood products in Japan. 2002 , 12, 383-93	5
765	AIDS-related <i>Pneumocystis carinii</i> pneumonia with disappearance of cystic lesions after treatment. 2002 , 41, 896-8	7
764	Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. 2002 , 162, 2545-56	34
763	Importance and epidemiology of infectious eye diseases. 2002 , 33, 145-90	5
762	High prevalence of osteonecrosis of the femoral head in HIV-infected adults. 2002 , 137, 17-25	127
761	Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. 2002 , 137, 381-433	234
760	The changing landscape of HIV-related lung disease in the era of highly active antiretroviral therapy. 2002 , 122, 768-71	4
759	Highly active antiretroviral therapy for HIV with tuberculosis: pardon the granuloma. 2002 , 122, 399-400	11
758	Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. 2002 , 46, 1336-9	85
757	An epidemiologic and clinicopathologic overview of AIDS-associated pulmonary Kaposi's sarcoma. 2003 , 75, 79-120	
756	Cytomegalovirus retinitis in the era of combined highly active antiretroviral therapy. 2002 , 15, 529-36, viii	22
755	Protease Inhibitor Combination Therapy and Decreased Condom Use Among Gay Men. 2002 , 95, 421-425	23
754	Secreted proteinases and other virulence mechanisms of <i>Candida albicans</i> . 2002 , 81, 114-28	26
753	Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. 2002 , 16, 161-70	24
752	Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. 2002 , 16, 2065-72	93

751	A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. 2002 , 16, 2175-82	218
750	Solid organ transplantation in the HIV-positive patient. 2002 , 7, 332-336	
749	Successful iterative drainage and partial hepatectomy for pyogenic liver abscess in a HIV seropositive patient. 2002 , 102, 59-62	2
748	Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. 2002 , 45, 3184-94	172
747	Immunology of diseases associated with <i>Malassezia</i> species. 2002 , 15, 21-57	224
746	Stem cell transplantation and gene therapy for HIV-related lymphomas. 2002 , 11, 765-75	7
745	Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 2002 , 41, 1529-38	18
744	Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. 2002 , 113, 91-8	123
743	Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 2002 , 133, 48-61	124
742	Fomivirsen for the treatment of cytomegalovirus retinitis. 2002 , 133, 552-6	68
741	Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. 2002 , 315, 573-86	17
740	Secreted aspartic proteases as virulence factors of <i>Candida</i> species. 2002 , 383, 1087-93	41
739	Antiretroviral drug toxicity -- a challenge for the hepatologist?. 2002 , 36, 283-94	94
738	Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. 2002 , 162, 433-8	101
737	Antiretroviral-drug resistance among patients recently infected with HIV. <i>New England Journal of Medicine</i> , 2002 , 347, 385-94	59.2 989
736	Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. 2002 , 20, 438-43	35
735	Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. 2002 , 41, 681-90	153
734	Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. 2002 , 41, 1195-211	119

733	Structured treatment interruption in patients infected with HIV: a new approach to therapy. 2002 , 62, 245-53		27
732	The challenge of viral reservoirs in HIV-1 infection. 2002 , 53, 557-93		500
731	Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. <i>New England Journal of Medicine</i> , 2002 , 346, 2039-46	59.2	561
730	Contribution of major diseases to disparities in mortality. <i>New England Journal of Medicine</i> , 2002 , 347, 1585-92	59.2	619
729	Clinical and Economic Implications of Non-Adherence to HAART in HIV Infection. 2002 , 10, 85-91		7
728	HIV disease and advanced age: an increasing therapeutic challenge. 2002 , 19, 647-69		48
727	[Adherence to antiretroviral therapy measured by pill count and drug serum concentrations. Variables associated with a bad adherence]. 2002 , 119, 286-92		15
726	Tumores asociados al sida. 2002 , 8, 3948-3958		
725	[Characteristics of bleeding from esophageal-gastric varices in patients with HIV infection]. 2002 , 25, 443-7		
724	[Factors predicting lack of adherence to highly active antiretroviral treatment]. 2002 , 20, 491-7		9
723	Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. 2002 , 16, 405-11		42
722	Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. 2002 , 16, 269-81		96
721	Serum malondialdehyde correlates with therapeutic efficiency of high activity antiretroviral therapies (HAART) in HIV-1 infected children. 2002 , 36, 341-4		7
720	Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. 2002 , 11, 1303-13		5
719	Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets. 2002 , 18, 999-1010		16
718	Detection of CMV in plasma and aqueous humor specimens from AIDS patients with CMV retinitis using the amplicor CMV test. 2002 , 34, 351-4		
717	Atazanavir: a novel HIV-1 protease inhibitor. 2002 , 11, 1295-301		43
716	Clinical implications of CNS penetration of antiretroviral drugs. 2002 , 16, 595-609		72

715	The role of immune reconstitution in cytomegalovirus infection. 2002 , 16, 89-95	6
714	Management of protease inhibitor-associated hyperlipidemia. 2002 , 2, 91-106	31
713	A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. 2002 , 14, 3-15	53
712	Prevalence of oral lesions in Mexican children with perinatally acquired HIV: association with immunologic status, viral load, and gender. 2002 , 16, 151-6	28
711	Self-reported adherence to antiretroviral treatment and degree of sense of coherence in a group of HIV-infected patients. 2002 , 16, 609-16	30
710	HIV/AIDS treatment and HIV vaccines for Africa. 2002 , 359, 2261-7	27
709	Protease inhibitors and cardiovascular outcomes in patients with HIV-1. 2002 , 360, 1747-8	405
708	Project Stronger Together: Protocol to Test a Dyadic Intervention to Improve Engagement in HIV Care Among Sero-Discordant Male Couples in Three US Cities. 2017 , 6, e170	31
707	Method Development and Validation for Multicomponent Analysis of Emtricitabine and Ritonavir in Bulk Drug by RP-HPLC. 2020 , 10, 137-144	1
706	Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. 2008 , 86, 970-7	31
705	Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. 2010 , 4, 515-528	68
704	Pharmacogenetics of Adverse Drug Reactions. 2006 , 65-89	1
703	Genetic variation in <i>Pneumocystis carinii</i> isolates from different geographic regions: implications for transmission. 2000 , 6, 265-72	196
702	Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy. 2012 , 35, 964-70	10
701	HIV-specific cellular immune responses are stimulated by structured treatment interruption in chronically HIV-1 infected Koreans. 2006 , 47, 282-6	2
700	KASL clinical practice guidelines: management of hepatitis C. 2014 , 20, 89-136	30
699	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139	58
698	Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. 2009 , 15, 3713-24	43

697	Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients. 2011 , 17, 2500-6	21
696	Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. 2014 , 20, 5353-62	13
695	Hepatitis C virus infection in the human immunodeficiency virus infected patient. 2014 , 20, 12132-43	20
694	Combination antiretroviral studies for patients with primary biliary cirrhosis. 2016 , 22, 349-60	15
693	Epidemiology, determinants, and management of AIDS cholangiopathy: A review. 2018 , 24, 767-774	28
692	Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. 2006 , 2, 159-166	6
691	Characteristics of HIV infection/AIDS in Korea. 2001 , 16, 1-7	5
690	Effect of Antiretroviral Therapy on Lipid Metabolism in HIV/AIDS Subjects in Cameroon. 2005 , 5, 78-82	4
689	Lipid Profile of Infected Patients Treated with Highly Active Antiretroviral Therapy in Cameroon. 2007 , 7, 670-673	3
688	HIV and older adults: clinical outcomes in the era of HAART. 2004 , 30, 16-24; quiz 55-6	7
687	Chemosensory declines in older adults with HIV: identifying interventions. 2006 , 32, 42-8	8
686	Promoting successful cognitive aging in adults with HIV: strategies for intervention. 2006 , 32, 34-41	24
685	Three-level global resource allocation model for hiv control: A hierarchical decision system approach. 2018 , 15, 255-273	5
684	Modelling the demographic impact of HIV/AIDS in South Africa and the likely impact of interventions. 14, 541-574	27
683	EBV and HIV-Related Lymphoma. 2009 , 1, e2009032	46
682	Unexpected low frequency of respiratory symptoms in an HIV-positive urban sub-Saharan population compared to an HIV-negative control group. 2019 , 20, 1010	2
681	Medical management of human immunodeficiency virus infection. 2008 , 56, 385-90	9
680	Impact of highly active antiretroviral therapy on ophthalmic manifestations in human immunodeficiency virus / acquired immune deficiency syndrome. 2008 , 56, 391-3	10

679	Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?. 2011 , 134, 787-800	18
678	HIV & immune reconstitution inflammatory syndrome (IRIS). 2011 , 134, 866-77	80
677	Amphotericin B for cryptococcal meningitis in HIV positive patients: Low dose versus high dose. 2007 , 11, 112-116	1
676	Oral manifestations of human immunodeficiency virus in children: An institutional study at highly active antiretroviral therapy centre in India. 2012 , 16, 195-202	13
675	Lipid Profile of Anti-Retroviral Treatment-Naïve HIV-Infected Patients in Jos, Nigeria. 2013 , 3, 26-30	21
674	Disparities in the Magnitude of Human Immunodeficiency Virus-related Opportunistic Infections Between High and Low/Middle-income Countries: Is Highly Active Antiretroviral Therapy Changing the Trend?. 2016 , 6, 4-18	14
673	Pathogenesis and treatment of human immunodeficiency virus lipodystrophy. 2012 , 16 Suppl 1, S20-6	19
672	HYBRID ON-OFF CONTROLS FOR AN HIV MODEL BASED ON A LINEAR CONTROL PROBLEM. 2015 , 52, 469-487	1
671	Health Protective Behaviors among Young People Living with HIV/AIDS. 2012 , S1,	4
670	Survival and predictors of mortality among human immunodeficiency virus patients on anti-retroviral treatment at Jinka Hospital, South Omo, Ethiopia: a six years retrospective cohort study. 2016 , 38, e2016049	20
669	Chronic obstructive pulmonary disease in adults with human immunodeficiency virus infection: a systematic review. 2011 , 03, 218-227	2
668	Causes of Death among HIV-Infected Adults Registered in Selected Anti-Retroviral Therapy Centers in North-Eastern India. 2015 , 05, 90-99	3
667	Liver transplantation in HCV/HIV positive patients. 2011 , 3, 21-8	9
666	Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus. 2013 , 5, 323-7	6
665	Disseminated toxoplasmosis in a patient with advanced acquired immunodeficiency syndrome. 2018 , 8, e2018012	5
664	Impaired diastolic function in naïve untreated human immunodeficiency virus infected patients. 2010 , 2, 98-103	14
663	HIV aspartyl protease inhibitors as promising compounds against Candida albicans Andr ^o Luis Souza dos Santos. 2010 , 1, 21-30	26
662	Mechanisms mediating the effects of alcohol and HIV anti-retroviral agents on mTORC1, mTORC2 and protein synthesis in myocytes. 2012 , 3, 110-20	13

661	Retrospective Clinical and Radiologic Evaluation of Nonsurgical Endodontic Treatment in Human Immunodeficiency Virus (HIV) Infection. 2006 , 7, 1-8	9
660	Short-term Success of Osseointegrated Dental Implants in HIV-positive Individuals: A Prospective Study. 2007 , 8, 1-10	22
659	Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus Type 1 Infection. 2007 , 50, 316	2
658	Dosage and Duration Effects of Korean Red Ginseng Intake on Frequency of Gross Deletions in the nef Gene. 2010 , 34, 219-226	11
657	Snake venom preparation for drug-resistant human immunodeficiency virus. 2008 , 28, 292-3	7
656	Elevated alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus coinfection. 2016 , 36, 288-91	2
655	Moderate-Intensity Exercise Improves Body Composition and Improves Physiological Markers of Stress in HIV-Infected Men. 2012 , 2012, 145127	19
654	Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. 2012 , 2012, 621565	28
653	An Emerging Concern-High Rates of Frailty among Middle-aged and Older Individuals Living with HIV. 2019 , 22, 190-198	3
652	Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. 2002 , 126, 182-90	64
651	Gender Reassignment Surgery in Human Immunodeficiency Virus-Positive Patients: A Report of Two Cases. 2015 , 42, 776-82	2
650	HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. 1999 , 131, 813-21	163
649	Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. 1999 , 131, 136-43	45
648	Cholangiocarcinoma and AIDS-related sclerosing cholangitis. 2000 , 132, 1006-7	12
647	Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. 2000 , 132, 182-90	155
646	Irreversible depletion of intestinal CD4+ T cells is associated with T cell activation during chronic HIV infection. 2021 , 6,	3
645	Considerations in the Management of a Kidney Transplant Patient With HIV. 2021 , 13, e18744	
644	Association of elevated plasma inflammatory biomarker levels with age-related macular degeneration but not cataract in persons with AIDS.. 2022 , 36, 177-184	1

- 643 Beeinflussung der Glukosetoleranz, B-Zell-Funktion und des Lipid Metabolismus bei HIV-1 infizierten Patienten unter der Therapie mit Proteaseinhibitoren. **2000**, 372-379
- 642 Effekte verschiedener antiretroviraler Therapien [Ergebnisse einer Langzeitübersicht bei 843 AIDS-Patienten der Jahre 1987-1998. **2000**, 240-246
- 641 The Role of Cytokines and Chemokines in HIV Disease at the Verge of the New Millennium. **2000**, 29-35
- 640 Anti-Retroviral Therapy and Resistance to Anti-Retroviral Drugs. **2000**, 221-242
- 639 HIV in der Transplantationsmedizin. **2000**, 568-574
- 638 ATLANTIC: Unverblindete, randomisierte prospektive Studie zum Vergleich konvergenter antiretroviraler Dreifachkombinationen mit einer Protease-Inhibitor-haltigen (divergenten) Standardtherapie nicht vorbehandelter HIV-Infizierter. **2000**, 230-234
- 637 Cystoid macular edema in a patient with acquired immunodeficiency syndrome and past ocular history of cytomegalovirus retinitis after initiation of protease inhibitors. **2000**, 107-111
- 636 An Activist Perspective on the Gay Community Living with HIV, Primary Care and Clinical Trials. **2000**, 387-401
- 635 Die antiretrovirale Therapie des HIV-infizierten Kindes. **2000**, 283-288
- 634 HIV-Infektion: CDC-Klassifikation und Lebensqualität. **2000**, 751-756
- 633 Immunrekonstitution bei stark immunsupprimierten Patienten unter HAART [Die kritischen ersten Monate. **2000**, 95-100
- 632 Reduction of Bronchoscopy Performances Should Be Included in the Advantages of Highly Active Antiretroviral Therapy (HAART). **2000**, 286-287
- 631 Evolving characteristics of AIDS-related lymphoma. **2000**, 96, 4084-4090
- 630 HIV and Blood Transfusion. **2001**, 251-278
- 629 T-bodies as antiviral agents. **2001**, 260, 271-300
- 628 AIDS in the Intensive Care Unit. **2001**, 137-191
- 627 AIDS/HIV: Drugs for Opportunistic Infections. **2001**, 61-107
- 626 HIV in America, 1981 to 2000: Therapeutic and Epidemiologic Considerations. **2001**, 9-17

625 AIDS-Related Interventional Procedures. **2001**, 263-284

624 HIV infection of the gastrointestinal tract. **2001**, 131-152

623 Imaging in AIDS. **2001**, 249-273

622 Screening for HIV infection in indigent women with newly diagnosed cervical cancer. **2001**, 27, 95-6

621 Screening for HIV Infection In Indigent Women With Newly Diagnosed Cervical Cancer. **2001**, 27, 95-96

620 AIDS and the lung in a changing world. **2001**, 56, 423-426

619 HIV-Infektion und Kaposi-Sarkom. **2002**, 1015-1074

1

618 Overview of the Biomedical Aspects of HIV and Its Impact on Older Adults. **2002**, 83-111

617 HIV-1 and the central nervous system. **2002**, 265, 183-95

14

616 CMVR DIAGNOSES AND PROGRESSION OF CD4 CELL COUNTS AND HIV VIRAL LOAD MEASUREMENTS IN HIV PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. **2002**, 3, 90-91

615 Providing health care for drug users. **2002**, 161-171

614 Gut Infection in HIV: Past, Present and Future. **2003**, 479-489

613 Antiretrovirale HIV-Therapie. **2003**, 93-99

612 Deutsch-Österreichische Richtlinien zur Antiretroviralen Therapie der HIV-Infektion (Juli 2002). **2003**, 59-87

611 Changing Patterns of Prophylaxis and Treatment of Bacterial and Viral Intestinal Infections. **2003**, 413-426

610 Methods for Assessing Body Composition in HIV-Associated Lipodystrophy. **2003**, 39-64

609 Human Immunodeficiency Virus InfectionsNeurological Manifestations. **2003**, 623-646

608 AIDS/HIV and Neurological Disease. **2003**, 66-76

607 Abnormalities in Lipid Metabolism in HIV. **2003**, 87-105

606 HIV infection and AIDS: present status of antiretroviral therapy. **2003**, 211-222

605 Aids und HIV-Infektion. **2003**, 1578-1594

604 HIV-Infektion und AIDS. **2003**, 253-263

603 Sektion II Praxis. **2003**, 1-340

602 Infectious Diarrhea. **2003**, 453-470

601 AIDS/HIV. 219

600 The individualized care of patients with HIV disease. **2003**, 280-334

599 Understanding antiretroviral therapy. **2003**, 378-395

598 THE IMMUNOLOGICAL AND VIROLOGICAL RESPONSE IN HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) INFECTED INDIAN INDIVIDUALS ON HAART THERAPY: A ONE-YEAR FOLLOW UP STUDY. **2003**, 21, 274-276 4

597 Divergent Mechanisms of Candidal Immunity at Different Anatomical Sites. **2004**, 259-277

596 The basic principles for combination therapy. **2004**, 41-51 1

595 A perspective of the history of HAART. **2004**, 25-40

594 Sex and Gender-Specific Issues in HIV Pathogenesis. **2004**, 923-930 1

593 The Role of Antiretroviral Therapy in Asia. **2004**, 407-419

592 Salvage therapy. **2004**, 99-113

591 Economic implication of HIV-1 resistance testing in overall clinical care. **2004**, 195-204 2

590 Nursing Perspectives in the Care of Persons with HIV Infection. **2004**, 1029-1043

589 Neuropathology of AIDS. **2004**, 773-799

588 Virale Infektionskrankheiten, Mykoplasmen-, Chlamydien- und Rickettsien-Infektionen. **2004**, 322-352

587 Guidelines for antiretroviral therapy. **2004**, 205-223

586 Immune reconstitution in HIV infection. **2004**, 127-140

585 AIDS Home- and Community-Based Waivers: Effects on Use of Services, Expenditures, and Survival. **2004**, 71, 60-77

584 AIDS-associated malignancies. **2005**, 22, 687-706

1

583 Enteral Nutrition in Human Immunodeficiency Virus Infection. **2005**, 486-497

582 The Ever-changing Face of AIDS: Implications for Patient Care. **2005**, 286-306

581 Multiorganinfektionen [komplexe klinisch-infektiologische Krankheiten]. **2005**, 47-112

580 Economics. **2005**, 307-323

579 The African Experience. **2005**, 351-373

0

578 La détermination d'une compensation optimale en univers risqué le cas des victimes contaminées par le virus du sida par transfusion ou injection de produits sanguins en France. **2005**, 115, 801

577 HIV/AIDS and the Surgeon. **2005**, 703-724

576 HIV/AIDS related vascular emergencies. **2005**, 545-554

575 HIV Protease (PR) and Cell Death. **2005**, 155-168

1

574 Involvement of Apoptosis in Complications of HIV and Its Treatment. **2005**, 405-420

573 Direct Effects of Anti-HIV Therapeutics on Apoptosis. **2005**, 441-445

572 Correlations between Apoptosis and HIV Disease Progression. **2005**, 355-379

- 571 HIV-1 Reservoirs and Residual Viral Replication during Highly Active Antiretroviral Therapy. **2005**, 457-474
- 570 Cachexia Associated with AIDS. **2005**, 143-164
- 569 Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. **2004**, 060721083724034
- 568 Lymphoma in the Immunosuppressed. **2006**, 542-565
- 567 Respiratory Disorders in Pediatric HIV Infection. **2006**, 578-591
- 566 Wat is het werkingsmechanisme van de (non)nucleoside analoga en de protease-remmers (HIV-therapie)? **2006**, 1731-1732
- 565 Retinal Disease in HIV-infected Patients. **2006**, 1625-1672
- 564 Management of Combined Inflammatory and Rhegmatogenous Retinal Detachments (AIDS and ARN). **2006**, 2499-2508
- 563 Targets for drug development Past and present. **2007**, 179-196
- 562 HIV Dementia: A Neurodegenerative Disorder with Viral Etiology. **2007**, 359-371
- 561 Cardiovascular Involvement in Acquired Immune Deficiency Syndrome. **2007**, 2371-2384
- 560 Efficacy and Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients. **2007**, 070131030710001
- 559 Epilogue. **2007**, 395-406
- 558 Coping with AIDS: The Challenges of an Evolving Disease. **2007**, 129-151
- 557 Treatment of Cardiovascular Manifestations of HIV. **2007**, 842-851
- 556 Fever of Unknown Origin in HIV Patients. **2007**, 65-78
- 555 Brazil. **2007**, 429-446
- 554 Antiretroviral treatment and care of HIV. **2007**, 86-104

553 Biological Basis and Clinical Significance of HIV Resistance to Antiviral Drugs. **2008**, 309-318

552 Development and Transmission of HIV Drug Resistance. **2008**, 149-159

551 Systemic Viral Infections and the Eye. **2008**, 4685-4698

550 Models of Care: HIV Care in the Urban USA. **2008**, 527-536

549 Acquired Immunodeficiency Syndrome (AIDS). **2008**, 425-453

548 Uveitis, Retinitis, and Chorioretinitis. **2008**, 504-508

547 HIV und AIDS. **2008**, 849-887

546 Retinal Manifestations of the Acquired Immunodeficiency Syndrome: Diagnosis and Treatment. **2008**, 2095-2106

545 Living-Donor Renal Transplantation in HIV Positive Recipients. **2008**, 137-147

544 US Cohorts review: The HIV Outpatient Study (HOPS) and the Multicenter AIDS Cohort Study (MACS). **2008**, 171-184

543 Country review: United States of America. **2008**, 151-170

542 Cohort studies in Brazil: Projeto Prá Onze. **2008**, 311-328

541 The OPTIMA Cohort. **2008**, 219-238

540 Pain and Use of Health Services Among Persons Living with HIV. **2009**, 285-319

539 Genotypic antiretroviral resistance testing at viral failure in people with HIV.

538 Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs. **2009**, 213-227

537 Natural History of HIV Infection and Evolution of Antiretroviral Therapy. **2009**, 1-13

536 Interactions Between Advanced Age and HIV Cognitive Impairment. **2009**, 369-391

535 Vitreous implants. **2009**, 173-187

534 Coronary Heart Disease in HIV-Infected Patients: Epidemiology. **2009**, 99-110

533 Opportunistic Infections. **2009**, 531-571

532 In Vitro Performance and Analysis of Combination Anti-infective Evaluations. **2009**, 1135-1149

531 HIV and the acquired immunodeficiency syndrome. **2009**, 701-708

530 An important clinical lesson from a patient infected with HIV with diabetic nephropathy and retinopathy. **2009**, 2009,

529 Human Immunodeficiency Virus: Resistance to Antiretroviral Drugs in Developing Countries. **2010**, 75-94

1

528 HIV Infection and the PNS. **2010**, 51-85

527 HIV Infection and Diabetes. **2010**, 617-642

526 Pulmonary Manifestations of Human Immunodeficiency Virus Infection. **2010**, 1727-1735

525 Antiretroviral Therapy for Human Immunodeficiency Virus Infection. **2010**, 1833-1853

524 Epidemiology and Surveillance of HIV Infection and AIDS Among Non-Hispanic Blacks in the United States. **2010**, 15-30

1

523 Human Immunodeficiency Virus Infection in Women. **2010**, 1781-1807

522 HIV for the Primary Care Physician. **2010**, 775-780.e1

521 Pulmonary Complications of Human Immunodeficiency Virus Infection. **2010**, 1914-1949

520 Opportunistic infections. **2010**, 964-974

1

519 Acquired Immunodeficiency Syndrome. **2010**, 161-175

518 AIDS and HIV Infection. **2010**, 1732-1750

517 Antiretroviral therapy for HIV. **2010**, 556-566

516 The immunocompromised patient. **2010**, 295-384

515 Manifestations ophtalmiques inflammatoires et infectieuses de l'infection par le virus de l'immunodficience humaine. **2010**, 303-324

514 Principles of management of HIV in the developed world. **2010**, 1026-1032

513 Superficial Candidiasis.

512 Bacterial Infections of the Lower Respiratory Tract.

511 Acquired immunodeficiencies.

510 Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy. 313-332

509 HIV and the Skin. 1-47

1

508 The Human Lung Microbiome. **2011**, 117-143

507 Fungal Infections Among Patients with AIDS. **2011**, 525-536

506 Acquired Immune Deficiency Syndrome. **2011**, 612-621

505 Human Immunodeficiency Virus Infection. **2011**, 1067-1072

504 Progress on Research for the Treatment of HIV/AIDS with Traditional Chinese Medicine in China. **2011**, 01, 104-109

1

503 Syndrome inflammatoire de reconstitution immune. **2011**, 195, 561-575

502 Poly-L-Lactic Acid for the Treatment of HIV-Associated Facial Lipoatrophy. **2012**, 691-705

501 Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons. **2012**, 9-13

1

500 Current and Future Treatment Guidelines for HIV. **2012**, 15-21

499 Prevention of Hepatitis Infection in HIV-Infected Patients. **2012**, 151-161

498 The HIV Epidemic in the USA: Current Trends, 2010. **2012**, 1-7

497 Lung Disease in Older Patients with HIV. **2012**, 227-252

496 New Challenges of the NAFLD and HIV Epidemics. 35-41

495 Human and Animal Retroviruses: HIV-1 Infection Is a Risk Factor for Malignancy. **2012**, 585-611

494 HIV/AIDS. **2011**, 1-16

493 Development and transmission of HIV drug resistance. **2012**, 155-167

1

492 Care of the Adult HIV-Infected Patient. **2012**, 248-260

491 Uveitis, Retinitis, and Chorioretinitis. **2012**, 498-503.e4

490 Efeito da terapia antirretroviral e dos nveis de carga viral no complexo mdio-intimal e no ndice tornozelo-bra em pacientes infectados pelo HIV. **2012**, 11, 123-131

489 CHAPTER 13:Cobicistat and Ritonavir as Pharmacoenhancers for Antiviral Drugs. **2013**, 451-481

488 A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era. **2013**, 7, 1332-5

1

487 Quantitative Assessment of the Effect of Pharmacist Counseling on Decisional Conflict. **2013**, 39, 689-699

2

486 Human immunodeficiency virus infection: living with a chronic illness. **2013**, 941-982

485 High-Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition. 1-38

484 To the Barricades: the Molecular Revolution. **2013**, 293-338

483 Analyse dmographique de la mortalit par sida en Espagne. **2013**, 68, 539

1

482 RNA Wave for the HIV Therapy: Foods, Stem Cells and the RNA Information Gene. **2013**, 03, 131-146

1

- 481 Determinants of clinician knowledge on aging and HIV/AIDS: a survey of practitioners and policy makers in Kampala District, Uganda. **2013**, 8, e57028
- 480 The Roles of Immune Regulatory Factors FoxP3, PD-1, and CTLA-4 in Chronic Viral Infection. **2013**, 49, 221-227
- 479 Alcohol and HIV: Experimental and Clinical Evidence of Combined Impact on the Lung. **2014**, 211-229
- 478 Genotypic antiretroviral resistance testing at viral failure in people with HIV.
- 477 Long-Term Outcome of Liver Transplantation in HIV-1-Positive Patients: 15-Year Follow-Up. **2013**, 2013, 1-8 0
- 476 Assessment of intima-media complex in carotid, femoral and right subclavian arteries for early investigation of atherosclerosis in HIV-infected patients. **2013**, 46, 333-340 1
- 475 Blood-Borne Viruses and the Kidney. **2014**, 269-279
- 474 Lung Cancer in HIV Infection. **2014**, 301-311
- 473 Human Immunodeficiency Virus. **2014**, 373-392
- 472 Mood Disorders, Delirium, and Other Neurobehavioral Symptoms and Disorders in the HAART Era. 393-410
- 471 HIV/AIDS. 191-220
- 470 Perioperative Therapie bei HIV-Infektionen. **1998**, 1107-1110
- 469 Strategies for second-line antiretroviral therapy in adults with HIV infection. **1999**, 458, 239-66 2
- 468 Initial Treatment for HIV Infection. **1999**, 229-237
- 467 Designing a Vaccine Against HIV. **1999**, 357-396
- 466 Acquired immunodeficiency syndrome, *Pneumocystis carinii* pneumonia, and the danger of prognostication: apples to apples. **1999**, 27, 1043-4 0
- 465 HIV infection: problems with patients' anaesthetic management and healthcare workers' exposure. **1999**, 12, 359-66
- 464 Cytokines in the evolution and treatment of AIDS-lymphoma. **1999**, 11, 516-21 2

- 463 Epstein-Barr Virus Infection and Primary Central Nervous System Lymphoma. 383-391
- 462 Mitochondrial Dysfunction and Lactic Acidosis in HIV Disease. 87-93
- 461 Neurologic Aspects of Palliative Care for HIV/AIDS. 487-497
- 460 Human Immunodeficiency Virus-Associated Malignancies. 169-183
- 459 HIV Infection and Stroke: the Changing Face of a Rising Problem. 45-56
- 458 Human Immunodeficiency Virus, *Pneumocystis carinii*, *Toxoplasma gondii*, and *Leishmania* Species. 389-400
- 457 Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase. **2014**, 9, e109823
- 456 Nanomedicine and HIV/AIDS. **2014**, 175-194
- 455 Evaluación de resistencia genotípica del VIH-1 en pacientes con fallo virológico de Guatemala. **2014**, 1, 5-12
- 454 Correlation between Asymptomatic Bacteriuria and HIV-1 Viral Load Level and CD4 Count in Pregnant Women on Antiretroviral Therapy in Niamey (Chad). **2015**, 05, 308-312
- 453 Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. **2015**, 1483-1502.e8
- 452 Management of Opportunistic Infections Associated with Human Immunodeficiency Virus Infection. **2015**, 1642-1665.e5
- 451 Legal Reasoning for Life Settlements Transaction in Japan. **2015**, 2015, 631_1-631_31
- 450 Pulmonary Manifestations of Human Immunodeficiency Virus Infection. **2015**, 1558-1566.e2
- 449 9. African-American Women and HIV: Clinical Considerations. **2015**,
- 448 A Study on Exoenzyme Activities of *Candida albicans* Isolated from Oral Cavities of HIV-Infected Patients on HAART. **2015**, 2,
- 447 Hematopoietic cell transplantation for HIV-related lymphomas. 217-232
- 446 Bibliography. 259-260

445 Acquired Immune Deficiency Syndrome. 1-16

444 Temperament, radzenie sobie ze stresem a jakość życia osób chorych na nowotwory. **2016**,

443 The Liver in Systemic Disease and Pregnancy. **2016**, 315-352

1

442 Introduction. **2016**, 1-5

441 Acquired Immune Deficiency Syndrome. **2016**, 293-330

440 HIV Infection and Diabetes. **2016**, 1-32

439 HIV. **2016**, 1181-1195

1

438 Twenty Years of Improved Perinatal Outcomes for Pregnancies Affected by HIV Infection. **2016**, 4,

437 STUDY OF THERAPEUTIC RESPONSE TO SECOND LINE ART REGIMEN IN TERTIARY CARE TEACHING HOSPITAL OF SOUTH INDIA. **2016**, 5, 1929-1933

436 An Estimation of Mortality Risks among People Living with HIV in Karnataka State, India: Learnings from an Intensive HIV/AIDS Care and Support Programme. **2016**, 11, e0156611

3

435 Cost-effectiveness of once-daily versus twice-daily regimens in the treatment of HIV infection in sub-Saharan Africa: a probabilistic decision model. 5, 2681

0

434 Host-Directed Antiviral Therapies [An Emphasis on HIV Post-Exposure Prophylaxis. **2016**, 4,

433 New era of liver transplantation for HIV-HCV Co-infected patients: A case report. **2017**, 1, 072-076

432 HIV Infection and Diabetes. **2017**, 773-804

431 HIV Prevention: Treatment as Prevention (TasP), Occupational Postexposure Prophylaxis (oPEP), Nonoccupational Postexposure Prophylaxis (nPEP), and Pre-exposure Prophylaxis (PrEP). **2017**, 59-71

0

430 In Vitro Performance and Analysis of Combination Anti-infective Evaluations. **2017**, 1329-1345

1

429 Could low level laser therapy and highly active antiretroviral therapy lead to complete eradication of HIV-1 in vitro?. **2017**,

428 ADHERENCE TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL. **2017**, 4, 1048-1052

427 Project Stronger Together: Protocol to Test a Dyadic Intervention to Improve Engagement in HIV Care Among Sero-Discordant Male Couples in Three US Cities.

426 Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women. **2017**, 4, 154-160

425 II. HIV Infection. **2017**, 106, 2320-2325

424 The Challenge of Sustainability: The Impact of DREAM Programme on the Social, Economic and Working Conditions of Patients with HIV/AIDS. **2018**, 61-67

423 *Toxoplasma gondii* as a Parasite in Food: Analysis and Control. 227-247

o

422 The effect of aerobic exercises on lipid profile of patients with human immunodeficiency virus infection undergoing highly active antiretroviral therapy: a protocol for a systematic review. **2018**, 14, 559-565

421 Association between chronic hepatitis C virus infection and myocardial infarction in people living with HIV in the United States.

420 La exclusi3n de las personas con VIH de los cuerpos uniformados de seguridad en Espa1a. **2018**, 209-243

419 New York City HIV Care Continuum Dashboards: Using Surveillance Data to Improve HIV Care Among People Living With HIV in New York City (Preprint).

418 Improvement in Socio-Economic Productivity of HIV Positive Individuals on Antiretroviral Treatment in a Private Setting in South India. **2019**, 09, 23-32

417 Aging and HIV Disease: Synergistic Immunological Effects?. **2019**, 1801-1818

416 Chagas Disease in Immunosuppressed Patients. **2019**, 265-296

415 Statistical Issues in HIV/AIDS Research. **2019**, 196-205

414 DISCORDANT RESPONSE OF CD4+ T LYMPHOCYTES TO ANTIRETROVIRAL THERAPY. **2019**, 11, 16-30

3

413 The Principles of Therapy for HIV-1 Infection. **2019**, 163-188

412 [HIV infection, from a death sentence to a chronic disease]. **2019**, 64, 14-19

411 Adherence to combination antiretroviral therapy among orphaned children in Dar es Salaam, Tanzania. **2019**, 20, 954

o

410 Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease.

- 409 Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice. **2019**, 17, 190-197 2
- 408 HIV Vertical Transmission DTSM Simulation Models: Global and National Perspective. **2020**, 87-126
- 407 Influence of sexual risk behaviour and STI co-infection dynamics on the evolution of HIV set point viral load in MSM.
- 406 Successful Pregnancy and Delivery with Intracytoplasmic Sperm Injection in HIV-Serodiscordant Couple: the First Case in Korea. **2020**, 35, e197
- 405 Increasing prevalence of HIV-1 Transmitted Drug Resistance in Portugal: implications for first line treatment recommendations.
- 404 Algorithm of treatment results HIV-infected patients with extra articular long bone fractures. **2020**, 27, 19-25
- 403 Genetic and reproductive toxicity of lamivudine, tenofovir disoproxil fumarate, efavirenz and their combination in the bone marrow and testicular cells of male mice. **2020**, 5, 1-10 0
- 402 Non-Neoplastic Pathology of the Gastrointestinal Tract: A Practical Guide to Biopsy Diagnosis. **2020**, ,
- 401 Trends in Hospitalisation for Human Immunodeficiency Virus in a Tertiary Hospital in Dar es Salaam, Tanzania: A Case study. **2020**, 4, 101-107
- 400 Non-Neoplastic Diseases of the Anal Canal. **2020**, 434-445
- 399 Normal Oesophageal, Gastric and Duodenal Mucosa. **2020**, 131-156
- 398 Durable Control of HIV-1 Using a Staphylococcus aureus Cas9-Expressing Lentivirus Co-Targeting Viral Latency and Host Susceptibility.
- 397 Transcriptomic and Genetic Profiling of HIV-Associated Neurocognitive Disorders. **2021**, 8, 721954 1
- 396 HIV-1 Protease and Reverse Transcriptase Inhibitory Activities of Roxb. Rhizome Extracts and the Phytochemical Profile Analysis: In Vitro and In Silico Screening. **2021**, 14, 2
- 395 Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China. **2021**, 14, 4529-4537 0
- 394 A Value-Added Health Systems Science Intervention Based on My Life, My Story for Patients Living with HIV and Medical Students: Translating Narrative Medicine from Classroom to Clinic. **2021**, 42, 659-678 0
- 393 Infectious diseases of the upper gastrointestinal tract. **2021**, 78, 70-87 1
- 392 Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission. **2021**, 22, 346-359 0

- 391 Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. **2021**, 76, 1032-1040 o
- 390 HIV in Older Adults. **2020**, 1-23
- 389 HIV Infection, HIV Therapy, and Bone Health. **2020**, 146-155
- 388 Acquired Immunodeficiency Syndrome. **2020**, 145-159
- 387 HIV in ICU. **2020**, 247-265 o
- 386 Trends of Cause of Death among Human Immunodeficiency Virus Patients and the Impact of Low CD4 Counts on Diagnosis to Death: a Retrospective Cohort Study. **2020**, 35, e355 o
- 385 Sociodemographic and Clinical Characteristics of Highly Active Antiretroviral Treatment-Naïve Human Immunodeficiency Virus-Seropositive Patients in Uyo, Nigeria: Are the Demographics Changing?. **2020**, 61, 345-350
- 384 Pre- and post-HIV test knowledge, attitude, behavior, and practice of people living with HIV and AIDS by questionnaire pattern. **2020**, 41, 53-57 o
- 383 Reflexões humanísticas em serviço de atendimento especializado em HIV. **2020**, 28, 34-37
- 382 Prevention and Treatment of SHIVAD8 Infection in Rhesus Macaques by a Potent D-peptide HIV Entry Inhibitor.
- 381 Optimal scale-up of HIV treatment programs in resource-limited settings under supply uncertainty.
- 380 Approach to Reporting Inflammatory Bowel Disease Biopsies. **2020**, 401-409 o
- 379 Ileal Pouch Anal Anastomosis. **2020**, 410-416
- 378 Diverticular Disease, Mucosal Prolapse, and Related Conditions. **2020**, 417-433
- 377 Drug-Induced Gastrointestinal Disease. **2020**, 65-83
- 376 Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report. **2020**, 6, 184
- 375 Duodenitis. **2020**, 206-214
- 374 Inflammatory Bowel Disease Diagnosis. **2020**, 325-356 1

373 Index. **2020**, 446-462

372 Complications of Inflammatory Bowel Disease. **2020**, 388-400

371 HIV Treatment Advances as Prevention. **2002**, 91-108

370 HIV in the ICU. **2005**, 117-125

369 Aids und HIV-Infektion. **2005**, 1655-1671

368 Aging and HIV Disease: Synergistic Immunological Effects?. **2009**, 949-964

367 Mitochondrial Toxicity and Lipodystrophy. **2006**, 281-302

366 New Reverse Transcriptase Inhibitors in Development. **2006**, 471-497

365 Ophthalmic Manifestations of Viral Diseases. **2006**, 179-206

364 Antiretrovirale Therapie. **2007**, 125-138

363 New HIV protease inhibitors for drug-resistant viruses. **2006**, 3, 79-88

362 Pars Plana Lensectomy. **2008**, 103-109

361 Virale Infektionskrankheiten, Mykoplasmen-, Chlamydien- und Rickettsien-Infektionen. **2007**, 330-363

360 Treatment Tactics and Complications After Surgical Treatment of HIV-Infected Patients With Extra-Articular Fractures of the Long Bones of Extremities. **2020**, 9, 369-376

359 Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): A randomized clinical trial. **2020**, 15, e0239452

1

358 A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort. **2020**, 7, ofaa567

0

357 Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients.

356 Functionalised Dendrimers: Potential Tool for Antiretroviral Therapy. **2020**, 16, 708-722

2

- 355 Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors. **2020**, 18, 415-425
- 354 The Effect of Health Insurance on Young Adult HIV Testing: Evidence from the Affordable Care Act Dependent Coverage Mandate.
- 353 Cardiac surgery in patients infected with human immunodeficiency virus. **2000**, 27, 356-60 9
- 352 The HAART side of resource allocation. **2003**, 169, 120-1 1
- 351 Adverse effects of antiretroviral therapy for HIV infection. **2004**, 170, 229-38 101
- 350 Incidence and duration of hospitalizations among persons with AIDS: an event history approach. **1999**, 33, 1611-38 11
- 349 Access and use of medications in HIV disease. **1999**, 34, 123-44 53
- 348 Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. **2000**, 35, 389-416 154
- 347 Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. **1999**, 160, 659-65 99
- 346 HIV related skin diseases clear with combination therapy. **1998**, 169, 225-6 2
- 345 Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. **2001**, 16, 850-9 17
- 344 Disease management--constructing optimal NRTI-based combinations: past, present, and future. **2006**, 8, 16
- 343 Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naïve, HIV-infected patients. **2006**, 8, 36 6
- 342 Anti-retroviral therapy induced diabetes in a Nigerian. **2007**, 7, 133-5 1
- 341 Financial burden of health services for people with HIV/AIDS in India. **2007**, 126, 509-17 19
- 340 The renaissance of fixed dose combinations: Combivir. **2007**, 3, 579-83 11
- 339 Review of tipranavir in the treatment of drug-resistant HIV. **2007**, 3, 641-51 5
- 338 Acute B cell lymphoblastic leukaemia and human immunodeficiency virus infection (HIV). **2002**, 71, 72-5

337	Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. 2008 , 10, 196	1
336	Oral manifestations in the era of HAART. 2003 , 95, 21S-32S	13
335	Constraints and prospects in the management of pediatric HIV/AIDS. 2006 , 98, 1252-9	3
334	HIV resistance and tolerability issues in antiretroviral therapy. 2001 , 93, 151-3	
333	Survival patterns among HIV+ individuals based on health care utilization. 2001 , 93, 214-9	11
332	Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. 2001 , 93, 243-50	28
331	Acquired immunodeficiency syndrome in older African Americans. 2002 , 94, 209-14	6
330	Association of complementary and alternative medicine use with highly active antiretroviral therapy initiation. 2008 , 14, 18-22	6
329	Capsaicin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine pulmonary arteries. 2009 , 15, BR1-5	5
328	Barriers to use of antiretroviral drugs in Rakai district of Uganda. 2010 , 10, 120-9	24
327	Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART). 2010 , 41, 126-37	6
326	Maraviroc: the evidence for its potential in the management of HIV. 2007 , 2, 1-14	
325	The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in CÔte d'Ivoire. 2007 , 12, 543-51	34
324	Unmasking Immune Reconstitution Inflammatory Syndrome (IRIS): A report of five cases and review of the literature. 2011 , 11, 95-103	4
323	HIV/AIDS and Colorectal Cancer: A Review in the Era of Antiretrovirals. 2008 , 4, 274-8	5
322	Intermuscular and subcutaneous adipose tissue distributions differ in HIV+ versus HIV-men and women. 2009 , 7, 73-78	2
321	Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview. 2011 , 36, 332-45	19
320	Targeting human immunodeficiency virus type 1 assembly, maturation and budding. 2007 , 2, 159-82	4

319	Factors associated with utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, Georgia. 2011 , 3, 63-70	5
318	The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya. 2008 , 43, 511-552	78
317	Patient factors impacting antiretroviral drug adherence in a Nigerian tertiary hospital. 2012 , 3, 138-42	10
316	[Descriptive aspects of HIV/AIDS in patients aged 50 years and over followed at the Treatment Center of Bafoussam - Cameroon]. 2012 , 12, 107	1
315	HIV and bone metabolism. 2011 , 11, 385-93	34
314	Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. 2013 , 13, 76-90	6
313	Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial. 2011 , 17, 30-5	4
312	Changes in the socio-demographics, risk behaviors, clinical and immunological profile of a cohort of the Puerto Rican population living with HIV: an update of the Retrovirus Research Center (1992-2008). 2010 , 102, 45-51	1
311	Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - a preliminary report. 2013 , 137, 942-9	9
310	Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India. 2013 , 137, 1145-53	2
309	A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. 2009 , 17, 14-25	120
308	Focus on the heart: alcohol consumption, HIV infection, and cardiovascular disease. 2010 , 33, 237-46	17
307	Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria. 2014 , 18, 631-6	6
306	Profile of Medicare Beneficiaries With AIDS: Application of an AIDS Casefinding Algorithm. 1998 , 19, 1-20	1
305	State Implementation of the AIDS Drug Assistance Programs. 1998 , 19, 1-24	
304	Cost and Financing of Care for Persons With HIV Disease: An Overview. 1998 , 19, 1-14	3
303	Overview. 1998 , 19, 1-3	
302	Health-Based Payment for HIV/AIDS in Medicaid Managed Care Programs. 1998 , 19, 1-20	

- 301 Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece. **2014**, 18, 100-6 7
- 300 Hospitalizations and its related factors in HIV/AIDS patients in Tehran, Iran. **2014**, 28, 70 2
- 299 Think Out of the Box, Think Out of the Eye Reappraisal of HIV/AIDS Retinopathy. **2014**, 3, 65-70
- 298 Long term impact of antiretroviral therapy--can we end HIV epidemic, the goal beyond 2015. **2014**, 140, 701-3 3
- 297 Prevalence of abnormal bone mineral density in hiv-positive patients in ibadan, Nigeria. **2013**, 3, 1-14 6
- 296 Serum protein electrophoresis under effective control of HIV-1 disease progression. **2014**, 13, 761-71 4
- 295 QSAR Study on Anti-HIV-1 Activity of 4-Oxo-1,4-dihydroquinoline and 4-Oxo-4H-pyrido[1,2-a]pyrimidine Derivatives Using SW-MLR, Artificial Neural Network and Filtering Methods. **2015**, 14, 69-75 14
- 294 Use of Compassionate Supply of Antiretroviral Drugs to Avoid Treatment Interruptions or Delayed Treatment Initiation among HIV-Positive Patients Living in Ontario: A Retrospective Review. **2015**, 10, 64-77 2
- 293 Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literature. **2015**, 1, 72-77 15
- 292 Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia. **2016**, 2, 32-5
- 291 The Indigenous Red Ribbon Storytelling Study: What does it mean for Indigenous peoples living with HIV and a substance use disorder to access antiretroviral therapy in Saskatchewan?. **2015**, 7, 27-40 2
- 290 HIV-HCV Coinfection. **2006**, 2, 357-365
- 289 Drug-Induced Liver Injury in HIV Patients. **2006**, 2, 430-437 7
- 288 How Feasible Is Renal Transplantation in HIV-Infected Patients?. **2017**, 12, 112-116 1
- 287 Atherosclerosis is associated with a higher risk of hepatic steatosis in HIV-infected patients. **2017**, 58, E219-E224 1
- 286 Dermatological conditions associated with HIV medication in a cohort of Greek patients initiating antiretroviral therapy: 1988-2013. **2018**, 4, 26-29
- 285 HIV-associated cognitive performance and psychomotor impairment in a Thai cohort on long-term cART. **2018**, 4, 41-47 10
- 284 Inflammation and outer blood-retina barrier (BRB) compromise following choroidal murine cytomegalovirus (MCMV) infections. **2018**, 24, 379-394 4

283	When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection. 2011 , 19, 126-31	9
282	Hepatitis C virus therapeutics: at the end of the beginning. 2012 , 20, 17-9	2
281	An HIV Patient with a Unilateral Decrease of Vision. 2017 , 5, 193-196	
280	Non-traumatic Unilateral Femur Neck Fracture in a Human Immunodeficiency Virus-Positive Septuagenarian Indian Male: A Unique Case Report. 2018 , 8, 75-77	
279	Influence of pharmacist intervention, based on CMO model, to improve activation in HIV patients. 2019 , 32, 40-49	3
278	Single-Tablet Regimens in the Treatment of HIV-1 Infection. 2016 , 33, 24S-30S	5
277	The effect of exercise training on disease progression, fitness, quality of life, and mental health in people living with HIV on antiretroviral therapy: a systematic review. 2015 , 1, 129-139	1
276	Pneumonia in HIV-Positive and HIV-Negative Patients: A Single-Center Retrospective Study. 2019 , 18, 238-243	0
275	HIV-associated Extracranial Arterial Aneurysms: A Systematic Review. 2020 , 8, 128-133	2
274	Bilateral sub-trochanteric femur fragility fractures in a patient on antiretroviral therapy: a case based discussion and review of literature. 2020 , 10, 121-126	
273	The clinical outcome of HIV infection at a tertiary care center in Riyadh, Saudi Arabia. 2020 , 41, 965-970	
272	Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. 1999 , 20, 1896-906	97
271	A Descriptive Study of HIV Patients Highly Adherent to Antiretroviral. 2020 , 2020, 1295-1304	
270	Screening CT of the brain determined by CD4 count in HIV-positive patients presenting with headache. 2000 , 21, 451-4	10
269	Reduction in cerebral oxygen metabolism in subcortical regions may be a biomarker of cognitive decline in people living with human immunodeficiency virus. 2021 ,	0
268	IRF7 and RNH1 are modifying factors of HIV-1 reservoirs: a genome-wide association analysis. 2021 , 19, 282	2
267	Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report. 2021 , 18, 90	0
266	Human Immunodeficiency Virus Infection and Out-of-Hospital Cardiac Arrest. 2021 ,	0

- 265 The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection.. **2021**, 227, 111661 0
- 264 Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. **2021**, 1
- 263 Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis. **2021**, 35, 467-473
- 262 Minimum redundancy maximal relevance gene selection of apoptosis pathway genes in peripheral blood mononuclear cells of HIV-infected patients with antiretroviral therapy-associated mitochondrial toxicity. **2021**, 14, 285 0
- 261 Toward Dietary Diversity Among Adult People Living With HIV in Public Hospitals in Southwest Ethiopia Using Theory of Planned Behavior. A Mixed Methods Study.. **2021**, 58, 469580211060805
- 260 Uptake Success and Cost Savings from Switching to a Two-Drug Antiretroviral Regimen.. **2021**,
- 259 HIV, Aging, and Comorbidities Research in Clinical Cohorts: 3 Lessons Learned Using Examples From the CNICS Cohort.. **2022**, 89, S10-S14
- 258 The clinical outcome of HIV infection at a tertiary care center in Riyadh, Saudi Arabia. **2020**, 41, 965-970
- 257 Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.. **2022**,
- 256 Immune Reconstitution Inflammatory Syndrome Induced by Complex Infection Presenting as Chronic Inflammatory Demyelinating Polyneuropathy in a Young AIDS Patient.. **2022**, 58, 0
- 255 Neurodegeneration Associated with HIV-1 in the Era of cART. **2022**, 1-30
- 254 Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV.. **2022**, 1
- 253 Systematic review and meta-analysis of COVID-19 vaccines safety, tolerability, and efficacy among HIV-infected patients. 0
- 252 Clinical Characteristics of HIV-Infected Patients with Venous Thromboembolism and Different CD4 T Lymphocyte Levels.. **2022**, 15, 613-620
- 251 Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019.. **2022**, 22, 63
- 250 Ex Vivo Differentiation of Resting CD4+ T Lymphocytes Enhances Detection of Replication Competent HIV-1 in Viral Outgrowth Assays.. **2022**, 2407, 315-331
- 249 Interplay between Selenium, Selenoproteins and HIV-1 Replication in Human CD4 T-Lymphocytes.. **2022**, 23, 1
- 248 Multiple opportunistic infections (pulmonary tuberculosis, complex and parvovirus B19) in a single patient.. **2022**, 23, 1319

247	Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment.. 2021 , 434, 167395	1
246	Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia.. 2022 , 9, ofac024	0
245	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.. 2021 ,	0
244	In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus.. 2022 , 144, 27-33	
243	Baseline HIV drug resistance testing: 12 U.S. jurisdictions, 2014-2019.. 2022 ,	0
242	The human immunodeficiency virus infection 40 years later. 2022 , 158, 218-218	
241	[Economic aspects of ambulatory and inpatient treatment of HIV positive patients]. 2003 , 44, 678, 681-90, 692-3	1
240	Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus.. 2022 , 10, 2050313X2010794	4
239	Anti-HIV aptamers Challenges and Prospects. 2021 ,	
238	Trends in the Epidemiology and Outcomes of Pneumocystis Pneumonia among Human Immunodeficiency Virus (HIV) Hospitalizations.. 2022 , 19,	0
237	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine.. 2022 , 14,	2
236	Inflammatory and immune markers in HIV-infected older adults on long-term antiretroviral therapy: persistent elevation of sCD14 and of proinflammatory effector memory T cells.	
235	Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort.. 2022 ,	0
234	Late cART Initiation Consistently Driven by Late HIV Presentation: A Multicenter Retrospective Cohort Study in Taiwan from 2009 to 2019.. 2022 , 1	0
233	Development and validation of a modified Cambridge Multimorbidity Score for use with internationally recognized electronic health record clinical terms (SNOMED CT).	0
232	The HIV Env Glycoprotein Conformational States on Cells and Viruses.. 2022 , e0182521	0
231	Mucocutaneous Manifestations of People Living with HIV in Current Antiretroviral Therapy Era.. 2022 ,	0
230	CD4 T cells are prone to be infected by HIV-1 and associated with HIV-1 disease progression.. 2022 , 23 Suppl 1, 106-114	

229	Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.. 2022 ,	0
228	Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection.. 2022 , 24, 1-12	0
227	Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.. 2022 , 17, e0261069	2
226	Small molecule based anti-virulence approaches against infections.. 2022 , 1-27	0
225	The human immunodeficiency virus infection 40 years later.. 2021 , 158, 218-218	0
224	Senotherapeutics in Cancer and HIV.. 2022 , 11,	1
223	Longitudinal Changes in, and Factors Associated with, the Frequency of Condomless Sex Among People in Care for HIV Infection, HIV Outpatient Study USA, 2007-2019.. 2022 , 1	0
222	Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon β a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. 2021 , 12, 767370	0
221	Incidence of lung and HPV-associated malignancies in HIV-infected patients.. 2021 , 36,	
220	Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database.. 2021 , 16, 72	4
219	Predictors of All-Cause Mortality among People with HIV in a Prospective Cohort Study in East Africa and Nigeria. 2021 ,	0
218	Healthcare utilization among persons living with HIV in Manitoba, Canada, prior to HIV diagnosis: A case-control analysis.. 2021 , 9564624211051615	
217	Years Since Diagnosis Among People Living With Diagnosed HIV in New York City.. 2021 , 333549211061325	
216	Trends of HIV-Related Cancer Mortality between 2001 and 2018: An Observational Analysis.. 2021 , 6,	1
215	Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status. 2021 , 12, 2919-2931	1
214	HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020.. 2021 , 10,	0
213	Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370. 2002 , 7, 185-193	68
212	Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy β Randomized Double-Blind Placebo-Controlled Study. 2003 , 8, 199-207	106

211 Autoimmunity and HIV infection. **2022**, 141-167

210 HIV-related lymphomas. 462-486

209 Data_Sheet_1.PDF. **2019**,

208 image_1.PDF. **2018**,

207 image_2.PDF. **2018**,

206 image_3.PDF. **2018**,

205 image_4.PDF. **2018**,

204 image_5.PDF. **2018**,

203 image_6.PDF. **2018**,

202 image_7.PDF. **2018**,

201 image_8.PDF. **2018**,

200 image_9.PDF. **2018**,

199 table_1.PDF. **2018**,

198 Data_Sheet_1.PDF. **2019**,

197 Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults. **2011**, 34, e321-9

10

196 Atherogenic index of plasma in highly active antiretroviral therapy-naïve patients with human immunodeficiency virus infection in Southeast Nigeria. **2014**, 18, 631

10

195 An HIV patient with a unilateral decrease of vision. **2017**, 5, 193

0

194 Evaluating Barriers to Viral Suppression among People with HIV in Santiago, Dominican Republic.. **2022**, 21, 23259582221096522

0

193	Systemic Viral Infections and the Eye. 2022 , 7515-7555	
192	The making of the one pill-Developing single tablet regimens for HIV and for HCV.. 2022 , 27, 13596535211067606	
191	HIV-1-Transmitted Drug Resistance and Transmission Clusters in Newly Diagnosed Patients in Portugal Between 2014 and 2019.. 2022 , 13, 823208	0
190	Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.. 2022 , e0222321	0
189	Kinetics of Chemokine Levels during Anti-HIV Therapy. 1999 , 4, 109-115	5
188	Patients Failing Saquinavir Therapy Require an Early Change to Indinavir before HIV-1 Viral Load Reaches High Levels. 1999 , 4, 117-121	
187	Effective Salvage Therapy for HIV-1 Infection [An Unmet Challenge. 1999 , 4, 59-60	6
186	Opportunistic Infections Shortly after Beginning Highly Active Antiretroviral Therapy. 1998 , 3, 229-231	15
185	Intensification of Background Antiretroviral Therapy with Abacavir during Low-Level Failure May Restore Optimal Suppression. 2000 , 5, 91-94	2
184	Amprenavir in Combination with Lamivudine and Zidovudine versus Lamivudine and Zidovudine Alone in HIV-1-Infected Antiretroviral-Naïve Adults. 2000 , 5, 215-225	23
183	Phenotypic HIV-1 Resistance Correlates with Treatment Outcome of Nelfinavir Salvage Therapy. 2000 , 5, 249-256	4
182	Effectiveness and Pitfalls of Initial Highly Active Antiretroviral Therapy in HIV-Infected Patients in Routine Clinical Practice. 2000 , 5, 243-248	9
181	Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up. 2000 , 5, 65-70	48
180	Antiretroviral Resistance Testing Comes of Age. 2000 , 5, 23-26	11
179	Antiretroviral Activity of Emtricitabine, a Potent Nucleoside Reverse Transcriptase Inhibitor. 2001 , 6, 83-88	13
178	Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naïve HIV-1-Infected Adults. 2001 , 6, 105-114	7
177	Pharmacological Exposure and the Development of Drug Resistance in HIV. 2001 , 6, 37-47	3
176	A Rational Approach to the Selection and Sequencing of Nucleoside/Nucleotide Analogues: A New Paradigm. 2001 , 6, 45-54	9

175	An Introduction to Nucleoside and Nucleotide Analogues. 2001 , 6, 1-14	21
174	Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to Didanosine. 2001 , 6, 41-46	4
173	A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study). 2002 , 7, 81-90	72
172	Baseline Thymic Volume is a Predictor for CD4 T Cell Repopulation in Adult HIV-Infected Patients under Highly Active Antiretroviral Therapy. 2002 , 7, 159-163	14
171	Efficacy and Safety of Twice-Daily versus Three-Times Daily Saquinavir Soft Gelatin Capsules as Part of Triple Combination Therapy for HIV-1 Infection. 2002 , 7, 199-209	2
170	Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. 2002 , 7, 257-266	19
169	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. 2002 , 7, 271-281	9
168	Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial. 2003 , 8, 163-171	33
167	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<200 Cells/Mm3) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). 2003 , 8, 233-237	6
166	Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations. 2003 , 8, 209-214	10
165	Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics. 2003 , 8, 191-198	12
164	A Controlled Phase II Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults. 2003 , 8, 279-287	30
163	Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. 2003 , 8, 347-354	7
162	Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088). 2003 , 8, 427-434	30
161	Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill. 2003 , 8, 471-478	37
160	Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme. 2003 , 8, 569-576	10
159	A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir. 2003 , 8, 507-518	6
158	Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals. 2003 , 8, 603-609	11

157	Long-Term Efficacy and Safety of Twice-Daily Saquinavir Soft Gelatin Capsules (SGC), with or without Nelfinavir, and Three Times Daily Saquinavir-SGC, in Triple Combination Therapy for HIV Infection: 100-Week Follow-Up. 2003 , 8, 37-42	4
156	Persistent Brain Abnormalities in Antiretroviral-Naive HIV Patients 3 Months after Haart. 2003 , 8, 17-26	59
155	Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes. 2003 , 8, 27-35	9
154	Construction, Training and Clinical Validation of An Interpretation System for Genotypic HIV-1 Drug Resistance Based on Fuzzy Rules Revised by Virological Outcomes. 2004 , 9, 583-593	5
153	Initiating Highly Active Antiretroviral Therapy and Continuity of HIV Care: The Impact of Incarceration and Prison Release on Adherence and HIV Treatment Outcomes. 2004 , 9, 713-719	81
152	Cost Effectiveness Analysis of Routine Use of Genotypic Antiretroviral Resistance Testing after Failure of Antiretroviral Treatment for HIV. 2004 , 9, 27-36	17
151	The Impact of HIV Antiviral Therapy on Human Papillomavirus (Hpv) Infections and Hpv-Related Diseases. 2004 , 9, 13-22	75
150	Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir. 2004 , 9, 221-227	11
149	Management of Dyslipidaemia in HIV-Infected Patients Receiving Antiretroviral Therapy. 2004 , 9, 649-663	8
148	The Correlation between Plasma Concentrations of Protease Inhibitors, Medication Adherence and Virological Outcome in HIV-Infected Patients. 2004 , 9, 753-761	12
147	The Problems Faced When Assessing the Prevalence and Incidence of Antiretroviral-Related Toxicities. 2004 , 9, 865-878	1
146	Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy. 2004 , 9, 979-985	3
145	Complications Associated with Nrti Therapy: Update on Clinical Features and Possible Pathogenic Mechanisms. 2004 , 9, 849-863	61
144	Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf- α and Tnf-Receptor Levels, and on Metabolic Parameters. 2004 , 9, 879-887	5
143	Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection. 2005 , 10, 13-28	13
142	The Steady-State Pharmacokinetics of Nelfinavir in Combination with Tenofovir in HIV-Infected Patients. 2005 , 10, 349-355	7
141	The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens. 2005 , 10, 459-467	10
140	The Safety and Tolerability of Z-100 in Patients Infected with HIV-1. 2006 , 11, 297-303	0

139	Muscle and Liver Lactate Metabolism in Haart-Treated and Naive HIV-Infected Patients: The Mitovir Study. 2005 , 10, 543-550	3
138	3?-Azido-2?,3?-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. 2006 , 11, 803-812	14
137	Improvement in Dyslipidaemia after Switching Stavudine to Tenofovir and Replacing Protease Inhibitors with Efavirenz in HIV-Infected Children. 2005 , 10, 917-924	31
136	Arterial Stiffness in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. 2005 , 10, 925-935	26
135	Efficacy and Safety of Indinavir/Ritonavir 400/100 mg Twice Daily plus Two Nucleoside Analogues in Treatment-Naive HIV-1-Infected Patients with CD4+ T-cell Counts <200 cells/mm ³ : 96-Week Outcomes. 2005 , 10, 911-916	9
134	Five-Year Follow up of Once-Daily Therapy with Emtricitabine, Didanosine and Efavirenz (Montana ANRS 091 Trial). 2007 , 12, 417-422	10
133	Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. 2008 , 13, 89-94	27
132	A Phase I/IIa Study with Succinylated Human Serum Albumin (Suc-HSA), a candidate HIV-1 Fusion Inhibitor. 2007 , 12, 273-278	5
131	The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV-Infected Adults in Cte D'Ivoire. 2007 , 12, 543-551	36
130	Late Presentation of HIV-Infected Individuals. 2007 , 12, 841-851	34
129	HIV Genotypic Resistance Testing to Optimize Antiretroviral Prescribing: Is There Room for Improvement?. 2007 , 12, 957-962	3
128	Use of Diet, Nutritional Supplements and Exercise in HIV-Infected Patients Receiving Combination Antiretroviral Therapies: A Systematic Review. 2008 , 13, 149-160	18
127	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. 2009 , 14, 349-357	32
126	Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env. 2009 , 14, 413-422	
125	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. 2009 , 14, 359-369	12
124	Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection. 2009 , 14, 381-392	
123	Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France January 1997 to December 2006. 2009 , 14, 567-575	22
122	The Status of HIV-1 Resistance to Antiretroviral drugs in Sub-Saharan Africa. 2008 , 13, 625-639	21

121	HIV Coinfection and Antiretroviral Therapy Enhances Liver Steatosis in Patients with Hepatitis C, but Only in those Infected by HCV Genotype other than 3. 2008 , 13, 1057-1065	11
120	Dried Fluid Spots for HIV Type-1 Viral Load and Resistance Genotyping: A Systematic Review. 2009 , 14, 619-629	51
119	Predictors of Virological Response in HIV-Infected Patients to Salvage Antiretroviral Therapy that Includes Nelfinavir. 2001 , 6, 47-54	8
118	Response to Antiretroviral Therapy among Patients Exposed to Three Classes of Antiretrovirals: Results from the EuroSIDA Study. 2002 , 7, 21-30	17
117	Frequency, determinants and consequences of delayed access to care for HIV infection in France. 2007 , 12, 89-96	40
116	Uridine Supplementation for the treatment of Antiretroviral Therapy-Associated Lipodystrophy: A Randomized, Double-Blind, Placebo-Controlled Trial. 2007 , 12, 97-106	12
115	Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome. 2008 , 13, 103-108	56
114	A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. 2006 , 11, 787-796	45
113	Increased Antiretroviral Potency by the Addition of Enfuvirtide to a Four-Drug Regimen in Antiretroviral-Naïve, HIV-Infected Patients. 2006 , 11, 47-51	16
112	Long-Term Highly Active Antiretroviral Therapy in Chronic HIV-1 Infection: Evidence for Reconstitution of Antiviral Immunity. 2006 , 11, 105-116	16
111	Low Genetic Barrier to Large Increases in HIV-1 Cross-Resistance to Protease Inhibitors during Salvage Therapy. 2006 , 11, 143-154	5
110	Boosted versus Unboosted Indinavir with Zidovudine and Lamivudine in Nucleoside Pre-Treated Patients: A Randomized, Open-Label Trial with 112 Weeks of Follow-Up (HIV-Nat 005). 2006 , 11, 223-232	11
109	Salvage Therapy with Atazanavir/Ritonavir Combined to Tenofovir in HIV-Infected Patients with Multiple Treatment Failures: Randomized Anrs 107 Trial. 2006 , 11, 213-222	5
108	Early Antiviral Treatment of Hepatitis C Virus Recurrence after Liver Transplantation in HIV-Infected Patients. 2006 , 11, 1061-1070	14
107	HIV-1 Transmission Cluster with M41L Bingleton Mutation and Decreased Transmission of Resistance in Newly Diagnosed Swedish Homosexual Men. 2006 , 11, 1031-1040	17
106	Durable HIV-1 Suppression with Indinavir after Failing Lamivudine-Containing Double Nucleoside Therapy: A Randomized Controlled Trial. 2001 , 6, 55-62	3
105	Oral and maxillofacial manifestations of human immunodeficiency virus infection. 2022 ,	
104	Association between gut microbiota and prediabetes in people living with HIV. 2022 , 3, 100143	

103 Blood-Borne Viruses and the Kidney. **2022**, 565-582

102 Infección por el virus de la inmunodeficiencia humana. **2022**, 13, 3329-3336

101 Exploring static and dynamic relationships between burden of disease and research funding in the United States. **2022**, 20,

0

100 Beyond Inhibition: A Novel Strategy of Targeting HIV-1 Protease to Eliminate Viral Reservoirs. **2022**, 14, 1179

1

99 Incidence, risk factors, and outcomes of acute kidney injury among hiv positive medical admissions at the Bamenda Regional Hospital. **2022**, 6, 068-073

0

98 Prevention and Initial Management of HIV Infection. **2022**, 175, ITC81-ITC96

2

97 Cardiovascular risk factors and markers of myocardial injury and inflammation in people living with HIV in Nairobi, Kenya: a pilot cross-sectional study. **2022**, 12, e062352

96 Telemedicine Use Among People with HIV in 2021: The Hybrid-Care Environment.

95 The Impact of Low-Level Viraemia on Virological Failure Results From a Multicenter HIV Antiretroviral Therapy Cohort Study in Yunnan, China. 9,

94 Altered white matter microstructure and neurocognitive function of HIV-infected patients with low nadir CD4.

0

93 A Review on Mycobacteriophages: From Classification to Applications. **2022**, 11, 777

92 Overweight and obesity and associated factors among adult ART patients at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia. **2022**, 8,

91 Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients. **2022**, 17, e0270770

90 Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature. 1-19

0

89 Endocrine and Metabolic Disorders. **2021**, 368-376

88 Toward Ending the HIV Epidemic: Temporal Trends and Disparities in Early ART Initiation and Early Viral Suppression Among People Newly Entering HIV Care in the United States, 2012-2018. **2022**, 9,

87 A trispecific Ab directed to HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.

86 Inflammatory and immune markers in HIV -infected older adults on long-term antiretroviral therapy: Persistent elevation of sCD14 and of proinflammatory effector memory T cells.

- 85 Can simplified antiretroviral drug combination therapies resist resistance?. **2022**, 36, 1597-1598
- 84 HIV Resistance Testing: Methods, Utility, and Limitations. **2000**, 5, 159-168 ○
- 83 Dawn of a new beginning- First renal transplant in patient with HIV in Nepal. **2022**, 7, 100108 ○
- 82 Pharmacogenetics of HIV therapy: State of the art in Latin American countries. **2022**, 45, ○
- 81 Revisiting Do People Living with HIV/AIDS Have Better Quality of Life? Findings from a cross-sectional study. **2022**, 0 ○
- 80 Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance. 1
- 79 The Potential of Moringa oleifera to Ameliorate HAART-Induced Pathophysiological Complications. **2022**, 11, 2981 ○
- 78 Cytomegalovirus coinfection among people living with HIV in China before and on cART: A retrospective study. ○
- 77 Serum globulin levels are associated with HIV reservoir size and immune restoration during long-term ART. ○
- 76 Individual risk prediction: Comparing random forests with Cox proportional-hazards model by a simulation study. ○
- 75 INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND): Protocol for a Pilot Randomized Controlled Trial in Uganda (Preprint). ○
- 74 Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study. ○
- 73 Clinical Characteristics and Prognostic Factors Impacting Clinical Outcomes in Cytomegalovirus Retinitis with or without HIV Infection. **2022**, Publish Ahead of Print, ○
- 72 Growing older with HIV in the Treat-All Era. **2022**, 25, ○
- 71 Pattern of HCV Genotypes in HIV/HCV Co-Infected Patients on Antiretroviral Therapy in Nigeria. **2022**, 4, 30-34 ○
- 70 Single-cell analysis of immune cell transcriptome during HIV-1 infection and therapy. **2022**, 23, 1
- 69 INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND): Protocol for a Pilot Randomized Controlled Trial in Uganda (Preprint). ○
- 68 Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects. 1-14 ○

- 67 Associations between drug and alcohol use, smoking, and frailty among people with HIV across the United States in the current era of antiretroviral treatment. **2022**, 240, 109649 ○
- 66 HIV-1 Spectrum Disease, Psychological Distress, and Cardiometabolic Risk. **2022**, 1415-1441 ○
- 65 cART Restores Transient Responsiveness to IFN Type 1 in HIV-Infected Humanized Mice. ○
- 64 Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing, China. 10, ○
- 63 The Role of the Social Determinants of Health on Engagement in Physical Activity or Exercise among Adults Living with HIV: A Scoping Review. **2022**, 19, 13528 ○
- 62 Characteristics of psychosocial interventions to improve ART adherence in people living with HIV: A systematic review. **2022**, 2, e0000956 ○
- 61 We are Getting Those Old People Things. Polypharmacy Management and Medication Adherence Among Adult HIV Patients with Multiple Comorbidities: A Qualitative Study. Volume 16, 2773-2780 ○
- 60 Outcomes of cataract surgery in patients with Human Immunodeficiency Virus infection in a developing country. ○
- 59 Neoplasms in People Living with Human Immunodeficiency Virus. 1-18 ○
- 58 Structure-based stabilization of SOSIP Env enhances recombinant ectodomain durability and yield. ○
- 57 Hidradenitis Suppurativa in Patients with HIV: A Scoping Review. **2022**, 10, 2761 ○
- 56 HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore. **2019**, 48, 133-138 1
- 55 Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors. **2022**, 117083 ○
- 54 The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia. **2022**, 8, 1167 ○
- 53 Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV. 095646242211379
- 52 Impact of highly active antiretroviral drug therapy (HAART) on biochemical, hematologic, atherogenic and anthropometric profiles of human immunodeficiency virus patients at a tertiary hospital in Owo, Nigeria. **2022**, 46, ○
- 51 To the Barricades THE MOLECULAR REVOLUTION. **2022**, 245-283 ○
- 50 Comparison of the design and methodology of Phase 3 clinical trials of bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature. ○

- 49 Towards a new combination therapy with vectored immunoprophylaxis for HIV: Modeling shock and kill strategy. **2023**, 355, 108954 ○
- 48 Asymptomatic HIV-Infected Patients Present Blood Parameters Changed, According to Use of Therapy and the CD4+ T Cells Count. 58, ○
- 47 Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV. **2022**, 14, 2626 1
- 46 Antiviral properties of porous graphene, graphene oxide and graphene foam ultrafine fibers against Phi6 bacteriophage. 9, ○
- 45 HIV-Associated Mycobacterium Avium Complex, Oral Candida, and SARS-CoV-2 Co-Infection: A Rare Case Report. Volume 15, 7037-7042 ○
- 44 CRISPR/Cas9: a tool to eradicate HIV-1. **2022**, 19, ○
- 43 The benefits of care: treated HIV infection and health-related quality of life among older-aged people in Uganda. 1-7 ○
- 42 Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV. Publish Ahead of Print, ○
- 41 PREVALENCE AND TEMPORAL TRENDS OF AUTOIMMUNE DISEASES IN PEOPLE LIVING WITH HIV.. 1
- 40 Mapping the interplay between NK cells and HIV: therapeutic implications. ○
- 39 Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield. 1
- 38 A new intervention strategy for an HIV/AIDS transmission by a general fractional modeling and an optimal control approach. **2023**, 167, 113078 1
- 37 Causes of Death and Factors Associated with Early Death Among Human Immunodeficiency Virus (HIV)-Infected Persons in Singapore: Pre-Highly Active Antiretroviral Therapy (HAART) and Peri-HAART. **2012**, 41, 563-570 ○
- 36 Patient Experience Evaluation of the CMO-Based Pharmaceutical Care Model vs Usual Care in People Living with HIV. Volume 15, 2991-3003 ○
- 35 The scene investigation, postmortem changes, and time of death. **2023**, 65-101 ○
- 34 The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses. **2023**, 11, 286 ○
- 33 New designs for HIV-1 integrase inhibitors: a patent review (2018-present). ○
- 32 Current Oral Manifestations of HIV Infection. **2001**, 29, 137-141 ○

- 31 THE ANALYSIS OF HOSPITAL MORTALITY AMONG PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS. **2008**, 91-94 ○
- 30 Bilateral Vestibuloplasty Utilizing Palatal Soft Tissue Grafts in an HIV-Positive Patient. **2009**, 37, 467-470 ○
- 29 Evaluation of Patient Experience With A Model of Coordinated Telematic Pharmaceutical Care Between Hospital and Rural Pharmacies in Spain: A Proof of Concept. Volume 16, 1037-1046 ○
- 28 Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes. **2023**, 91, 104549 ○
- 27 Neurodegeneration Associated with HIV-1 in the Era of cART. **2022**, 1999-2028 ○
- 26 Defining multimorbidity in people with HIV –what matters most?. Publish Ahead of Print, ○
- 25 Telemedicine Use Among People With HIV in 2021: The Hybrid-Care Environment. **2023**, 92, 223-230 ○
- 24 Prevalence and risk factors for subclinical atherosclerosis amongst adults living with HIV in University of Abuja Teaching Hospital, Gwagwalada. 5, ○
- 23 Surgery for Infectious Retinitis - When Medical Therapy Is Not Sufficient: The Moacyr E. Alvaro Pan-American Lecture 2023. 1-9 ○
- 22 Integrated Care as a Model for Interprofessional Disease Management and the Benefits for People Living with HIV/AIDS. **2023**, 20, 3374 ○
- 21 High-Flow Nasal Cannula Oxygen Therapy versus Non-Invasive Ventilation in AIDS Patients with Acute Respiratory Failure: A Randomized Controlled Trial. **2023**, 12, 1679 ○
- 20 Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401 ○
- 19 A truncated HIV Tat demonstrates potent and specific latency reversal activity. ○
- 18 Cryptococcal Meningitis: Differences between Patients with and without HIV-Infection. **2023**, 12, 427 ○
- 17 Emergence of Multidrug Resistance Microbes: Bacteria, Fungi, and Viruses. **2023**, 28-67 ○
- 16 Head and neck squamous cell carcinoma in HIV patients. **2023**, 31, 78-82 ○
- 15 Health-related quality of life and associated factors among people living with HIV/AIDS in Sichuan, China: A cross-sectional study. 11, ○
- 14 Sequelae and mortality in patients with HIV/AIDS and Progressive Multifocal Leukoencephalopathy: Systematic review and case series in the Brazilian Amazon. 4, ○

- 13 Targeted plasma proteomics identifies MICA and IL1R1 proteins associated with HIV-1 reservoir size. **2023**, 26, 106486 ○
- 12 A large portion of diabetes cases in sub-Saharan African populations with HIV represent drug-induced diabetes. ○
- 11 Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/ μ l on ART. **2023**, 18, e0283648 ○
- 10 HIV Reservoir: How to Measure It?. **2023**, 20, 29-41 ○
- 9 RNase P Ribozyme Effectively Inhibits Human CC-Chemokine Receptor 5 Expression and Human Immunodeficiency Virus 1 Infection. **2023**, 3, 93-103 ○
- 8 Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males. **2023**, 18, ○
- 7 HIV infection and cardiovascular pathology. **2023**, 22, 3370 ○
- 6 People living with HIV, HCV and HIV/HCV coinfection in intensive care in a German tertiary referral center 2014-2019. ○
- 5 HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006-2022. **2023**, 15, 991 ○
- 4 The Humanized Mouse Model: What Added Value Does It Offer for HIV Research?. **2023**, 12, 608 ○
- 3 Incomplete immune reconstitution and its predictors in people living with HIV in Wuhan, China. ○
- 2 Nutritional and Lifestyle Therapy for NAFLD in People with HIV. **2023**, 15, 1990 ○
- 1 THE POTENTIAL PLACE OF TENOFOVIR IN ANTIRETROVIRAL TREATMENT REGIMENS. **2001**, 55, 704-709 ○